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1“STUDIES ON HETEROCYCLIC COMPOUNDS”
A comprehensive summary of the work to be incorporated in the thesis en-
titled “STUDIES ON HETEROCYCLIC COMPOUNDS” included investigations per-
taining to CINNOLINE  and its derivatives.
The aim of research is to be develop a new bioactive entities, especially with
antimicrobial and antitubercular activities bearing a heterocyclic ring system namely
cinnoline.
Our strategy is based on literature precedents that the combination of fused
bicyclic system with pharmacologically active heterocyclic entities in molecular frame
work, which may result in compounds with better drug potential. Bicyclic compounds
with heteroatoms have a wide range of physiological activities including bacteri-
cidal, fungicidal, antitubercular, psychotropic, antitumor, spasmolytic, vasodilator
etc. Among their vast number of synthesized heterocyclic compounds, derivatives
of cinnoline were found to have the most promising tuberculostatic activity.
Keeping in association with cinnoline of various activities, it was thought
worthwhile to synthesize some novel heterocycles, which have been described as
under.
PART-I : STUDIES ON ISOXAZOLES
Isoxazole derivatives represents one of the modest classes of compounds
possessing wide range of therapeutic activities such as antidepressants, muscle
relaxant, antidiabetic, antiinflammatory, analgesic etc. With a view to getting better
therapeutic agent and to evaluate its pharmacological profile, different type of
isoxazole have been designed and synthesized, which have been described as
under.
2SECTION-I: Synthesis and biological screening of 6-Chloro-3-[(2E)-3-arylprop-
2-enoyl]cinnolin-4(3H)-one
The chalcones of Type-(I) have been synthesized by the condensation of 3-
acetyl-6-chlorocinnolin-4(3H)-one with various aldehydes.
SECTION-II : Synthesis and biological screening of 6-Chloro-3-(5-aryl
isoxazol-3-yl)-cinnolin-4(3H)-one
Isoxazole derivatives of Type-(II) have been synthesized by the condensation
of the chalcones of Type-(I) with hydroxylamine hydrochloride in presence of sodium
acetate in acetic acid.
PART-II : STUDIES ON PYRAZOLINES
Pyrazolines as a class of heterocyclic compounds have been studied exten-
sively for the past several years. They are associated with broad spectrum of bio-
logical activities like anticancer, anticonvulsant, insecticidal, antipyratic etc. Keep-
ing in view of these diversified biological activities, we have undertaken the synthe-















Type-(II)               R = Aryl
3have been described as under.
SECTION-I : Synthesis and biological screening of 3-(1-Acetyl-5-aryl-4,5-
dihydro-1H-pyrazol-3-yl)-cinnolin-4(3H)-one
Pyrazoline derivatives of Type-(III) have been synthesized by the condensa-
tion of the chalcones of Type-(I) with hydrazine hydrate in glacial acetic acid.
SECTION-II : Synthesis and biological screening of 6-Chloro-3-(1-Phenyl-
5-aryl-4,5-dihydro-1H-pyrazol-3-yl)-cinnolin-4(3H)-one
Pyrazoline derivatives of Type-(IV) have been prepared by the condensation
of the chalcones of Type-(I) with phenyl hydrazine.
PART-III: STUDIES ON CYANOPYRIDINE
In recent years, much interest has been focused on the synthesis of pyridines


















R = ArylType - IV
4antibacterial,  antimalarial,  antihypertensive, anti fungal, anticonvulsant etc.
Consideraing these facts we thought it is worthwhile to synthesize some novel de-
rivatives in association with cinnoline nucleus in search of better potential drugs.
SECTION-I: Synthesis and biological screening of 2-Amino-4-aryl-6-(6-
chloro-4-oxo-3,4-dihydrocinnolin-3-yl)nicotinonitrile
Cyanopyridine derivatives of Type-(V) have been synthesized by the reaction
of the chalcones of the Type-(I) with malononitrile in presence of ammonium ac-
etate.
Part-IV: STUDIES ON NICOTINONITRILE
Nicotinonitrile derivatives have been reported to have various biological ac-
tivities like antibacterial, antifungal, antihypertensive, antiviral, antiinflammtory, etc.
From the above facts led us to prepared better therapeutic agents which have been
described as under.
SECTION-I: Synthesis and biological screening of 4-Aryl-6-(6-chloro-4-
oxo-3,4-dihydrocinnolin-3-yl)-2-oxo-1,2-dihydropyridine-3-
carbonitrile
Nicotinonitrile  derivatives of Type-(VI) have been synthesis of the chalcones








R = ArylType - V
5PART- V: STUDIES ON CYANOPYRAN
Cyanopyran derivatives have been reported to have various pharmacologi-
cal activities like antibacterial, antisecretary, antiviral, antifungal etc. In order to
develope better medicinally important compounds, it was considered of interest to
synthesize some cyanopyran derivatives shown as under.











Type - (VII)            R = Aryl
Cyanopyran derivatives of Type-(VII) have been synthesized by the reac-
tion of the chalcones of Type-(I) with malononitrile in pyridine.
PART-VI: STUDIES ON INDAZOLES










Type - VI  R = Aryl
6anticancer, antiinflammatory, anticonvulsant, antipyretic etc. With a view to prepare
more potential drugvalue compounds we have carried out the synthesis of indazole
derivatives, which have been briefed as under.
SECTION-I: Synthesis and biological screening  of  Ethyl-6-aryl-4 -(6-
chloro-4-oxo-3,4-dihydrocinnoline-3-yl)-2-oxocyclohex-3-
ene-1-carboxylate
Cyclohexenone derivatives of Type-(VIII) have been synthesized by the
cyclocondensation of the chalcones of Type-(I) with ethyl acetoacetate in presence
of sodium ethoxide.
SECTION-II: Synthesis and biological screening of 6-Chloro-3-(4-Aryl-3-
oxo-3,3a,4,5-tetrahydro-2H-indazol-6-yl)-cinnolin-4(3H)-one
Indazole derivatives of Type-(IX) have been prepared by the condensation of
cyclohexenone derivatives of Type-(VII) with hydrazine hydrate.


















7PART-VII: STUDIES ON BENZOTHIAZEPINE DERIVATIVES
Various types of benzothiazepine derivatives shows wide range of biological
activity such as anticancer, antifungal, antimicrobial, antitubercular, antidiabetic etc.
With a view to get better therapeutic agents, we have synthesized different types of
benzothiazepine derivatives which have been described as under.
SECTION-I: Synthesis and biological screening 6-Chloro-3-(2-aryl-2,3
-dihydro-1,5-benzothiazepine-4-yl)cinnolin-4(3H)-one
Benzothiazepine derivatives of Type-(X) have been prepared by condensation
of chalcones of Type-(I) and 2-amino thiophenol in presence of piperidine.
PART-VIII: STUDIES ON THIAZOLE DERIVATIVES
Thiazole and its derivatives endowed with wide range of therapeutic activities
like antimicrobial, antitubercular, anticancer, antidiabetic, antiinflammatory etc. In
order to prepare compounds possesing better biological activities, it was considered
worthwhile to synthesize thiazole derivatives shown as under.
SECTION-I Synthesis and biological screening of (1E)-Aryl-[4-(6-chloro-
4-oxo-3,4-dihydrocinnolin-3-yl)-1,3-thiazol-2-yl]hydrazone








8Thiazole derivatives of Type-(XI) have been prepared by condensation of bromo
acetyl cinnoline and different types of thiosemicarbazones, which was prepared by
condensation of aryl aldehyde and thiosemicarbazide.
PART-IX: STUDIES ON PYRIMIDINE DERIVATIVES
Pyrimidine derivatives are biologically important products and their synthesis
and chemistry have received remarkable attention. It has been reported that pyrimi-
dine derivatives are associated with various biological activities like antifungal, anti
tubercular, antibacterial, herbicidal etc. These valid observations prompted us to
synthesize some pyrimidine derivatives with the hope that they might be important
therapeutic nucleus of choice, which have been described as under.
SECTION-I: Preparation and biological screening of 3-(2-Amino-6-
-arylpyrimidin-4-yl)-6-chlorocinnolin-4(3H)-one
















Type-(XI) R = Aryl
9Pyrimidine derivatives of Type-(XII) have been prepared by the reaction of the
chalcones of Type-(I) with guanidine hydrochloride in presence of alcoholic potas-
sium hydroxide.
SECTION-II: Preparation and microbial evaluation of 6-Chloro-3-(6-aryl-
2-mercapto-3,4-dihydropyrimidin-4-yl)cinnolin-4(3H)-one
Pyrimidine derivatives of Type-(XIII) have been synthesized by the reaction of the
chalcones of Type-(I) with thiourea in presence of alcoholic potassium hydroxide.
The constitution of all above products has been supported by elemental analy-
ses and spectral studies like IR, 1H NMR and Mass spectroscopy. The purity of the
compounds synthesized was checked by TLC.
In vitro study on multiple biological activities:
q All the compounds have been evaluated for their antibacterial activity towards
Gram +ve and Gram -ve bacterial strains and antifungal activity towards
Aspergillus niger at a concentration 40 mg/ml. The biological activities of
the synthesized compounds have been compared with standard drugs.
q Some of the selected compounds have been sent to Tuberculosis Antimicro
bial Acqistion Coordinating Facility (TAACF)  Alabama, USA,  for antimicro-









bial  data of synthesized compound. The compounds have been screened
for their in vitro biological assay like antitubercular activity towards a strain
of Mycobacterium tuberculosis H37Rv at a concentration of 6.25 mg/ml
using Rifampin as a standard drug.
Date:
Signature of Guide Signature of Student
(Dr. H. S. Joshi) (Patel Mayur R.)
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Studies  on  Heterocyc l i c  . . .
Stud ies   on  Cinno l ine  . . .
INTRODUCTION
The discovery of cinnoline or 1,2-diazanaphthalene or benzo[c]pyridazine dates
from, but the compound and its derivatives have not received the attention accord re-
lated heterocyclic nitrogen compounds. The first synthesis of cinnoline was reported in
1883 by von Richter1. A number of substituted cinnolines have been described as
dyes2-6.
SYNTHETIC ASPECTS
The diazonium chloride obtained from o-amino phenylpropiolic acid was heated
in water solution at 700C. Cooling caused the separation of 4-hydroxycinnoline-3-car-
boxylic acid in quantitative yield. When this acid was heated above its melting point,
carbon dioxide was liberated and 4-hydroxy cinnoline was formed in nearly theoretical
yield. Distillation of 4-hydroxy cinnoline with zinc dust furnished a small amount of ba-
sic oil, which was assumed to be cinnoline.
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When diazonium salts prepared from certain o-aminophenylethylenes are allowed
to stand, cinnolines are formed. When diazotized 3-amino-4-isopropenylbenzoic acid
was allowed to stand at room temperature it undergo to ring closure to 4-methylcinnoline-
7-carboxylic acid was found by Widman8,9.
Stoermer, Gaus and Fincke10,11, extended this method. Diazotization of the sub-
stituted o-aminophenylethylene was followed by cyclisation, which usually occurred
spontaneously at room temperature in nearly quantitative yield.
Borsche and Herbert12 diazotized 2-amino-5-nitroacetophenone and allowed the
diazonium salt solution to stand at room temperature. The product, 4-hydroxy-6-
nitrocinnoline, separated in 80 % yield.
Koelsch13 carried out a similar diazotization and ring closure.
The reaction of a dicarbonyl compound with hydrazine to form an azines is well
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ration of cinnolines from certain 1,4-dicarbonyl compounds. An example is provided by
Heiduschka and Khudadad14, who synthesized ethyl 1,5-dimethyl-11-isopropyldibenzo
[f, h] cinnoline-4-carboxylate (V) by the condensation of “retoxyleneaceto acetic ester”
(IV) with hydrazine.
 Reaction of phenyl hydrazine with ethyl cyclohexanoxalate gave 5, 6, 7, 8-
tetrahydro-4-hydroxy-2-phenyl-3(2)-cinnoline (VII)
15,16
. Reaction of phenyl hydrazine with
acetonyl cyclohexanone (VIII) furnished 1, 4, 5, 6, 7, 8-hexahdro-3-methyl-1-phenyl
cinnoline (IX).
Closely related to these reactions with phenyl hydrazine is the synthesis of 3, 7-
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5-Chloro-4-hydroxy-3-phenyl cinnoline (XII) was obtained in low yield by Pfannstiel
and Janecke18, and 3-phenyl-cinnoline-4-carboxylic acid (XIV) was considered to be
the product obtained by Stolle and Becker19 in the following reactions.
A dihydrazino compound has also been used for the preparation of a cinnoline.
When 2,2'-dihydrazinobiphenyl (XV) was heated with hydrochloric acid under pressure,
Tauber20 was able to obtain benzo[c]cinnoline (XVI) in quantitative yield. Tauber like-
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In 1935, Hata, Tatematsu and Kubota21 obtained 3,8-dimethoxybenzo[c]cinnoline
(XVIII) as a by product in their synthesis of 2,7-dimethoxydiphenylene oxide by treat-
ment of tetraazotized 2,2'-diamino-4,4'-dimethoxy biphenyl (XVII) with copper sulphate.
The conversion of a few azo compounds to cinnolines has been reported. The
preparation of benzo[c]cinnoline has been described in a patent1 which calls for the
fusion of azobenzene with aluminium chloride and sodium chloride at 1200C. 3,8-dim-
ethyl benzo[c]cinnoline was similarly prepared from m.m’-diazobistoluene at 1000C in
25 % yield; 3,8-tetramethyldiaminobenzo[c]cinnoline, from m,m’-azobisdimethylaniline
at 1000C in 40 % yield.
The addition of dimethyl azodicarboxylate to styrene provides the only examples
of cinnoline formation by means of a Diels-Alder reaction22. Methylstyrene,
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REACTION MECHANISM
Mechanism of cinnoline nucleus can be explain on the basis of following three




(i) Amine react with nitrous acid to yield diazonium salts via a number of intermedi-
ate species. This reaction is called Diazo reaction. Since it was discovered by
Johan Peter Griess (1858) it is referred to as Griess Diazo reaction23,24.
The various steps involved in the diazo reaction are as under:
(ii) Diazonium salts reacts with aromatic amines, phenols and active mathylene group
to give azo compounds having the general formula  ArN=NAr . The reaction is
known as coupling reaction. The coupling reaction is electrophilic substitution
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Ethoxide ion attacks on active methylene group and takeup proton and forms
carbonion (I). In another way sodium ion attacks on diazonium salt and forms cation
(II), which on reaction with carbonion of ester to forms diazo derivatives.
(iii) In third step of cyclization, aluminium chloride withdraw electron from the acyl-
oxygen bond and facilitates the initial heterolysis. The resulting cation then at














+ EtOH + Na+
N NR Cl
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THERAPEUTIC IMPORTANCE
Heterocyclic annelated pyridazines attract considerable attention, which mainly
arises from the large variety of interesting pharmacological activities observed with
pyridazine derivatives25. The modern discovery26 of a natural antifungal, antibiotics,
containing this heteroarene system, most probably will stimulate even broader inter-
est in 1,2-diazine chemistry. On the other hand, derivatives of cinnolines and their
benzo and heterocyclic analogs exhibit biological activity in various areas, including
antihypertensive, antithrombotic, antitumor, antisecretory and bactericidal activities27-
30. 4-Amino-cinnolines became of recent importance due to their antimicrobial, anti-
histamine and insecticide properties31, its derivatives have been extensively utilized
as intermediate for the synthesis of fused cinnolines of potential biological activity32-35.
A. M. Amer
36
 et al. have reported the synthesis and potential biological activity of
cinnoline.
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Furthermore, Jones Geraint47 have synthesized 1,4-dihydro-4-oxo-3-cinnolinyl
propionates (I) and tested as immunosuppressants. Stanczak  A. et al.48 have also
synthesized and checked the action on the central nervous system of N2-substituted
cinnoline derivatives.
Garc ia  and co-workers 49 have repor ted hypotens ive act iv i ty  o f  3-
hydrazinethieno(2,3-h)cinnoline. Holland D. and co-workers50 have prepared cinnoline-
3-propionic acids as an orally active antiallergic substances. 3-(2-pyridinyl)-4(1H)-
cinnoline-N-oxide (II) are reported as the antisecretory agents51.
Moreover, Barraja et al.52 and Cirrincion
53 
have synthesized indolo[3,2-
c]cinnolines and reported them as an antiproliferative, antifungal, antibacterial and an-
tileukemic agents. 1,2-Malonyl-1,2dihydro cinnoline (III) reported as antiinflammatory,
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Yu Y. et al.55 have synthesized substituted dibenzo[c,h]cinnolines and reported
them as topoisomerase I-targeting anticancer agents. Moreover, Brzezinska E. et al.56
prepared 4-amino-3-cinnoline carbixylic acid derivatives and tested for antibacterial
properties, while Vingkar et al.57 reported (6-chloro-cinnolinyl)thiazoles (IV) as anti-
microbial agents.
Hennequin Laurent et al.58 prepared cinnoline compounds (V) having
antiangiogenic and vascular activity. Nakao, Toyoo et al.59 also prepared cinnoline
derivatives having antiinflammatory and antiallergic activity.Lunt E. et al.60 synthesized
4-amino cinnolines as antiprotozoal agents.
Nargund L. V. et al.61 synthesized substituted 4-arylaminopyrimido[5,4-c] cinnoline
as antibacterial agent. Stanczak A. et al.62 noted that some 4-amino-3-cinnoline carboxy-
lic acid derivatives and dioxo-1,2,3,4-tetrahydropyrimido[5,4-c]cinnolines possessed some
important biological activity. Yarnal S. M. et al.63 studies on aryl amino cinnolines (VI) and
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Marshall P. A. et al.64 have studied cinnolinyl isobenzofuranes (VII) for central
nervous system. Schenker F. et al.65 have reported the antihypertensive action of bicy-
clic 3-hydrazinocinnoline. Pandey Anjali et al.66 noted that 4-quinazolinyl-1-
piperazinecarboxamides useful as kinase inhibitors for treatment of proliferative dis-
eases.
Some cinnoline derivatives are used as a drugs  such as 1-ethyl-1,4-dihydro-4-
oxo[1,3]-dioxolo[4,5-g]cinnoline-3-carboxylic acid (VIII), known as Cinoxacin and used
as antibiotics. Some other derivatives of cinnolines are used as pesticide  such as
Sinofem 1-(4-chlorophenyl)-1,4-dihydro-5-(2-methoxy)-4-oxo-cinnoline-3-carboxylic
acid (IX) used as plant growth regulators.
Summarize some of the studies in this area, and indicate that in preparing po-
tentially useful biologically active agents of all classes, cinnoline rings may replace
pyridazine, naphthalene or quinoline rings to produce active compounds, which may
be less toxic, have different psychological disposition and/or different modes of me-
tabolism or detoxification, and thus impart desirable properties.
Literature survey revels that the novel cinnoline derivatives have the unique elec-
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ronic and optical properties of various materials including dyes, light emitting di-
odes and molecular devices. They possess drug potential activities. Looking to the
diversified pharmacological activity, it appeared of interest to synthesized some
isoxazole, pyrazoline, cyanopyridine, cyclohexenone, indazole, thiazole, thiazepine,
thiopyrimidine etc. bearing 3-acetyl-6-chloro-cinnolin-4(3H)-one moiety in order to
achieving compounds having better therapeutic activity. These studies are described
in the following parts.
Studies on cinnoline derivatives
PART-I : Synthesis and biological screening of isoxazole derivatives
PART-II : Synthesis and biological screening of pyrazoline derivatives
PART-III : Synthesis and biological screening of cyanopyridine
derivatives
PART-IV : Synthesis and biological screening of nicotinonitrile
derivatives
PART-V : Synthesis and biological screening of cyanopyran derivatives
PART-VI : Synthesis and biological screening of indazole derivatives
PART-VII : Synthesis and biological screening of benzothiazepine
derivatives
PART-VIII : Synthesis and biological screening of thiazole derivatives
PART-IX : Synthesis and biological screening of pyrimidine derivatives
28
Studies  on  Heterocyc l i c  . . .
Stud ies   on  Cinno l ine  . . .
REFERENCES
1. Richter, V. v.: Ber. 16, 677-83 (1883).
2. I. G. Farbenindustrie, A. G.: German patent 513,206 (1928); Chem. Abstr.,  25, 1266 (1931);
Friedlaender 17, 650-1 (1932).
3. I. G. Farbenindustrie, A. G.: German patent 555,182 (1931); Chem. Abstr.,  26, 5214 (1932);
Friedlaender 19, 2018-20 (1934).
4. I. G. Farbenindustrie, A. G.: German patent 577,631 (1933); Chem. Abstr.,  28, 654 (1934);
Friedlaender 20, 462-3 (1932).
5. Societe pour L’industrie Chimique a Bale: Swiss patent 189,407 (1937); Chem. Abstr., 31,6898
(1937).
6. Societe pour L’industrie Chimique a Bale: Swiss patent 194,341 (1938); Chem. Abstr., 32,7284
(1938).
7. Busch, M., and Rast, A.; Ber. 30, 52107 (1897).
8. Widman, O.; Ber. 17, 722-7 (1884).
9. Widman, O.; Ber. 42, 4216-17 (1909).
10. Stoermer, R., and Gaus, O.; Ber 45, 3104-13 (1912).
11. Stoermer, R., and Fincke, H.; Ber. 42, 3115-32 (1909).
12. Borsche, W., and Herbert, A.; Ann. 546, 293-303 (1941).
13. Koelsch, C. F.; J. Org. Chem. 8, 295-9 (1943).
14. Heiduschka, A., and Khudadad, C.:; Arch. Pharm. 251, 682-700 (1913).
15. Auwers, K. v.; Ann. 453, 211-38 (1927).
16. Ebel, F., Huber, F., and Brunner, A.; Helv. Chim. Acta., 12, 16-19 (1929).
17. Ruggli, P., and Straub, O.; Helv. Chim. Acta., 21, 1084-1100 (1938).
18. Pfannstiel, K., and Janecke, J.; Ber. 75B, 1096-1107 (1942).
19. Stolle, R., and Becker, W.; Ber. 57B, 1123-4 (1924).
20. Tauber, E.; Ber. 29, 2270-2 (1896).
21. Hata, K., Tatematsu, K., and Kubota, B.; Bull. Chem. Soc. Japan 10, 425-32 (1935).
22. Diels, O., and Alder, K.; Ann. 450, 237-54 (1926).
23. P. Griess,  Ann., 1858, 106, 123.
24. P. Griess, Ann., 1862, 121, 257.
25. Quintela J.M., Veiga M.C. and Alvarez-Sarandes R., Monatsh. Chem., 127, 537 (1996) and refer-
ences therein.
29
Studies  on  Heterocyc l i c  . . .
Stud ies   on  Cinno l ine  . . .
26. Grote R., Chen Y., Zeeck A., Chen Z., Zähner H., Mischnick L.P. and König W.A., J. Antibiotics,
41, 595 (1988).
27. Cignarella G., Barlocco D., Pinna G.A. and Curzu M.M., Acta. Chim. Slov., 41, 173 (1994).
28. Cignarella G., Barlocco D., Pinna G.A., Loriga M., Curzu M.,M., Tofanetti O., Germini M., Cazzulani
P. and Cavaletti E., J. Med. Chem., 32, 2277 (1989).
29. Lown J.W., Morgan A.R., Yen S.F., Wang Y.H. and Wilson W.D., Biochem., 24, 4028 (1990).
30. Miyamoto K., Matsumoto J. and Nakamura S., Jap. Patent. 02 29 570 (1990); C.A., 113, 97619
(1990).
31. Singerman G.M., Chem. Heterocycl. Compd., 27, 1 (1973).
32. Nargun L.V.G. and Nargund K.S., Arzneim. Forsch., 45, 1131 (1995).
33. Barrett D., Sasaki H., Tsutsumi H., Murata M., Teraswa T. and Sakane K., J. Org. Chem., 60, 3928
(1995).
34. Stanczak A., Kwapiszewski W., Szadoska A. and Pakulska W., Pharmazie, 49, 406 (1994).
35. Abbady M.S., Radwan S.M. and Bakhite E.A., Indian. J. Chem. Sec B, 32, 1281 (1993).
36. Amer A.M., El-Bermaui M.A., Ahmed A.F.S. and Soliman S.M., Monatsh. Chem., 130, 1409 (1999).
37. Jones, Geraint Ger. Offen. 2,438,413 (Cl. CO7D), 13 Mar 1975, Brit. Appl. 42,173/73, 07 Sep.
1973; 22 pp.
38. Holland, David; Jones, Geraint; Marshall, Paul W.; Tringham, Gwenda D. J. Med. Chem. 19(10),
1225-8 (1976).
39. Hay, James Volney U. S. 4,033,751 (Cl. 71-92; AO1N9/22), 05 Jul 1977, Appl. 678,707, 20 Apr
1976; 9 pp.
40. Savaranan, J.; Manjunath, K. S. Indian J. Pharm. Sci. 1998, 60(5), 330-332.
41. Abbady, M. S.; Radwan, S. M.; Bakhite, E. A. Indian J. Chem., Sect. B 1993, 32(B)(12), 1281-4.
42. Nakao, Toyoo; Takai, Masaw; Fukamachi, Hiromi; Ohashi, Hiroshi. Jpn. Kokai Tokkyo Koho JP
11 189,586 [99189,586] (Cl. CO7D215/22), 13 Jul 1999, Appl. 1997/358,639, 25 Dec 1997; 40 pp.
43. Conrad, Robert A.; White, William A. U. S. US 4,379,929 (Cl. 544-234; CO7D237/28), 12 Apr 1983,
Appl. 245,564, 19 Mar 1981; 9 pp.
44. Gavini E, Juliano C, Mule A, Pirisino G, Murineddu G, Pinna G A. Arch Pharm (Weinheim) 2000
Oct; 333(10): 341-6.
45. Tahara, Tetsuya; Kawakami, Minoru; Takehara, Shuzo; Sakamoro, Masamitsu. PCT Int. Appl. WO
86 01,506 (Cl. C07d237/36), 13 Mar 1986, JP Appl. 84/178, 789, 28 Aug 1984; 27 pp.
46. Hay, James Volney U.S. 4,033,751 (Cl. 71-92; AO1N9/22), 05 Jul 1977, Appl. 678,707, 20 Apr
1976; 9 pp.
30
Studies  on  Heterocyc l i c  . . .
Stud ies   on  Cinno l ine  . . .
47. Jones, Geraint Ger. Offen. 2,438,413 (Cl. C07D), 13 Mar 1975, Brit. Aappl. 42,173/73, 07 Sep
1973; 22pp.
48. Stanczak A, Kwapiszewskiw, Szadowska A, Pakulska W. Pharmazie 1994 Jun; 49(6) 406-12.
49. Garcia-Dominguez N, Ravina E, Santana L, Teran C, Garcia-Mera G, Orallo F, Crespo M, Fontenla
J A. Arch Pharma (Weinheim) 1988 Oct 321(10) 735-8.
50. Holland D, Jones G, Marshall P W, Tringham G D. J. Med. Chem. 1976 Oct; 19(10):1225-8.
51. Connor, David T.; Yound, Patricia A.; Von Strandtmann, Maximilian U.S. 3,973,020 (Cl. 424-250;
A61K31/495), 03 Aug 1976, Appl. 611,120, 08 Sep 1975; 3pp.
52. Barraja P, Diana P, Lauria A, Passannanti A, Almerico A N, Minnei C, Longu S, Cengiu D, Musiu C,
La Colla P. Bioorg. Med. Chem. 1999 Aug; 7(8): 1591-6.
53. Cirrincione G, Almerico E, Barraja P, Mingoia F. Farmaco 1995 Dec; 50(12): 849-52.
54. Siegfried A. G. Fr. 1,393,596 (Cl. A61, Co7d), March 26, 1965; Swiss Appl. Feb 26, 1963; 18pp.
55. Yu Y. Singh S K, Liu A, Li T K, Liu L F, LaVoie E J. Bioorg. Med. Chem. 2003 Apr; 11(7): 1475-91.
56. Brzezinska E, Stanezak A, Dchockiz.; Acta Pol. Pharma. 2003 Jan-Feb; 60(1): 15-20.
57. Vingkar, Sharvani K.; Bobade, A. S.; Khadse, B. G.; Indian Journal of Heterocyclic Chemistry
2001, 11(1), 35-38 (Eng).
58. Hennequin, Laurent Francois Andre. PCT Int. Appl. WO 02 12,228 (Cl. C07D403/12), 14 Feb 2002,
EP Appl 2000/402,255, 9 Aug 2000; 123 pp (Eng).
59. Nakao, Toyoo; Takai, Masaw; Fukamachi, Hiromi;Ohashi, Hiroshi,; Jpn. Kokai Tokkyo Koho JP
11 189,586 [99189,586] (Cl. C07D215/22), 13 Jul1999, Appl. 1997/358,639,25 Dec 1997; 40pp.
(Japan).
60. Lunt E, Washbourn K, Wragg W R.; J Chem. Soc., (Perkin) 1968; 9: 1152-5.
61. Nargund L V, Nargund K S.; Arzneimittelforschung: 1995 Oct; 45 (10): 1131-2.
62. Stanczak A, Lewgowd W, Pakulska W.; Pharmazie 1998 Mar; 53(3) : 156-61.
63. Yarnal, S. M.; Badiger, V. V.; J Karnatak Univ. Sci., 1984, 29, 82-6 (Eng).
64. Marshall, Philip A.; Mooney, Brett A,; Prager, Rolf H.; Ward, A. David; Aust. J. Chem., 1981,
34(12), 6127(Eng).
65. Schenker, E.; Salzmann, R. Arzneim. Forsch. 1979, 29(12), 1835-43.
66. Pandey, Anjali; Scarborough, Robert M.; Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara,
Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji. PCT Int. Appl. WO 02 16,351 (Cl.
CO7D403/12), 28 Feb 2002, US Appl. PV 226,122,18 Aug 2000; 61 pp.
31Studies on heterocyclic ...
Studies on Isoxazoles ...
INTRODUCTION
The growing potent literature of recent years demonstrate that chalcone, be-
ing a very active intermediate through which novel heterocycles with good medicinal
profile can be designed. The presence of keto-ehtylenic linkage in general, gives the
compound a great synthetic importance. This is well illustrated by benzalacetophenone
or phenyl styryl ketone or phenyl acrylophenone names as chalcone first coined by
Kotanecki and Tumbor1.
SYNTHETIC ASPECT
A considerable variety of methods are available for the preparation of chal-
cones. The most convenient method for the preparation of chalcone consist is con-
densing an appropriate aryl methyl ketone with an appropriate aromatic aldehyde us-
ing a suitable condensing agent.
The other condensing agents employed in several cases and sometimes ad-
vantages are Hydrogen chloride2,3, Zinc chloride and Acetic anhydride4, Phosphorus
oxychloride5, Borax solution
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acid9 and Organocadmimum compounds10.
Besides the condensation of an aldehyde with ketone, the other methods used
are,
1. Fries rearrangement of aryl cinnamates11,
2. Friedel craft’s cinnamoylation12,
3. Nencki reaction with cinnamic acid on an aromatic compounds13,
4. Diazo coupling of phenyl diazonium chloride with benzoyl acrylic acid14.
REACTION MECHANISM
Chalcone proceeds through Clasien-Schmidt condensation15,16 and the process
is catalysed in the presence of relatively strong base to form α, β-unsaturated alde-
hyde or a ketone.
IMPORTANCE OF CHALCONE
In recent years an increasing number of groups have become interested in chal-
cone and related compounds since they are finding extensive use in several medicinal
and industrial fields.
1. The chalcones are natural biocides17-19 and are well known key intermediates in
the synthesis of heterocyclic compounds exhibiting biological activities20-23.
2. The chemical reactivity of α, β-unsaturated carbonyl system 24,25 present in chal
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pyrazo l ines 26,  isoxazo les 27,  cyanopyr id ines 28,  cyanopyrans 29,
nicotinonitriles30, indazoles31, pyrimidines32-34, thiazepines35, pyranones36,
piperidone37 etc.
3. The chalcones are used as starting compounds to synthesize naturally occurring
flavanones, flavenes, flavanols
38,39 etc.
4. The chalcones have also been found to be useful in arriving at the structure of
several naturally occurring products like hemlock tannins40, phloretin41 and
cyanomalcurin42.
5. The structure of some naturally occurring pigments like chrysin, galangin,
kaempferol and quercetrol were established by their synthesis from suitably sub
stituted chalcones43.
6. Chalcone and their derivatives also have been found applicable as stabi-
lizers photosensitive materials, polymerization catalyst, fluorescent whitening
agents and organic brightening agents e.g. methyl chalcones and 4-chloro chal-
cone are patented as light stabilizing agent for polivinylidine44.
7. Chalcones react with a number of metal ions this reaction has been reported for
the detection of Fe(II)42 in presence of Sr and Ba ions. Trihydroxy chalcone was
used as an analytical reagent for amperometric estimation of copper45 and spec-
trophotometric study of germanium46.
THERAPEUTIC IMPORTANCE
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Kumar S. K. et al.63 have prepared novel boronic chalcone derivatives as antitu-
mor agents. Some derivatives of chalcones as antimicrobial agents were reported by
Bekhit, Adnan A. et al.64. Cinnamoyl piperidinobutyrophenone (I) reported by Carr, A.
A. et al.65 as antipsycotic agents.
Chalcones are potential biocides, because some naturally occurring antibiot-
ics66 and aminochalcones67,68 probably owe their biological activity in the presence of
the α, β-unsaturated carbonyl group. Nelson, G. L. et al.69 synthesized the analogs of
prostaglandin (II).
Some dihydrochalcones are well known for their sweetening property70,71 and
appear to be non-nutritive sweeteners. A dihydrochalcone ‘Uvaretin’ from Uvaria
acuminata has shown antitumor activity72 in lymphocytic leukemia test. V. K. Ahluvalia









35Studies on heterocyclic ...
Studies on Isoxazoles ...
Moreover, Zwagstra, M. E. et al.74 synthesized chalcone (IV) and reported as
antiallergic agent. Anti invasine and herbicidal activity of 1,3-diaryl propenones has
been reported by Parmar, V. S. et al.75. Ezio et al.76 have been reported chalcones
having a valuable antiproliferation activity both on sensitive cancerous cell and on cell
which are resistant to common.
The compound 4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-1-piperazine
acetic acid ethyl ester (V) has been marketed under the name of ‘Cinepazet’ used as
vasodilator. The other 5-methoxy-2-methyl-1-(1-oxo-7-phenyl)-1H-indole-3-acetic acid
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Chalcones have served as starting material for several synthetic manipulations and a
versatile synthon in organic synthesis. Furthermore, it is well documented in literature
that the majority of cinnoline derivatives possess pharmacologically proven therapeutic
potential. Though extensive research work has been reported on acetyl cinnoline de-
rivatives, relatively very known so far, about cinnoline derivatives. This enthused us to
synthesize the chalcone derivatives presuming that these chemical entity with 6-chloro-
3-acetyl-cinnolin-4(3H)-one in conjugation with unsaturated carbonyl system may have
a good therapeutic importance, that’s why we have been described in following section.
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INTRODUCTION
In 1888, Clasien suggested an isoxazole structure (I), a product from the reac-
tion of 1,3-diketone with hydroxylamine77. Subsequently Clasien and his students laid
down a solid foundation for the chemistry of isoxazole. Isoxazoles are a group of het-
erocyclic compounds containing two heteroatoms in five membered ring: Nitrogen and
Oxygen.
It was shown to possess the typical properties of an aromatic system but under
certain reaction conditions, particularly in reducing or basic media , it becomes highly
labile. Isoxazoles when substituted in the 3,5-positions are stable to alkali but when 3-
position is vacant, the ring is opened in the presence of cold alkaline media to give
ketonitriles and when 5-position is vacant, the ring is opened in the presence of hot
alkaline media to give nitriles and carboxylic acids.
Quilico78 made the most important contribution to the chemistry of isoxazoles in
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Well known sulpha drug, sulphamethoxazole and antibiotic oxamycin or cycloserain is
D4-amino-3-isoxazolidinone both contains isoxazole type of nucleus suggesting
isoxazoles and its derivatives have better therapeutic values in the field of medicinal
chemistry.
SYNTHETIC ASPECT
Isoxazole ring system have the pair of heteroatoms adjacent. The most useful
route to prepare is start with a 1,3-dicarbonyl80 compound and bring about cyclization
with a reagent to N-O bond; this is hydroxylamine for isoxazoles.
Isoxazole81 itself may be prepared by the action of hydroxylamine on proparg-
ylaldehyde.
The most convenient preparation 82 is the reaction between 1,1,3,3-tetraethoxy
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Isoxazole is also synthesized the condensation of acetylenic carbonyl83 com-
pounds with hydroxylamine hydrochloride.
Fanshave and Crawley84 prepared by isoxazole from α, β-unsaturated carbonyl
compounds, hydroxylamine hydrochloride and KOH in methanol.
Recently, Beatrice et al.85 prepared isoxazoles by one pot reaction under micro-
wave irradiation. S. Balaic et al.86 have been reported the reaction of 1,3-diketones
with hydroxylamine hydrochloride on silica gel under microwave irradiation to generate
isoxazole derivatives.
THERAPEUTIC INTEREST
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A few pharmacological active isoxazoles are known. Momose, Yu et al.95 have
prepared the isoxazole derivatives (I) which were used for prevention and treatment of
diabetes.
Moreover, Shiongogi and Co. Ltd.96 reported as antipyratic, analgesic antiin-
flammatory, and anticough properties. Misra R. N. et al.97 prepared N-[5-[[[5-alkyl-2-
oxazolyl]methyl]thio]-2-thiazolyl]carboxamides (II) as an inhibitors of cyclin dependent
kinase.
Allen, Larry et al.98 reported that (αS,5S)- 4-amino-3-chloro-4,5-dihydro-5-
isoxazoleacetic acid was used to inhibit g-glutamyl transpeptidase from human pan-
creatic carcinema cell. Vekariya, N. A. et al.99 synthesize the isoxazole derivatives and
reported it as potential anticancer agents. Hanifin, J. W. et al.100 was used isoxazole
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Recently, Hashimoto, H. et al101 prepared 4-(4-cycloalkyl/aryl-oxazol-5-
yl)benzenesulfonamides for the treatment of rheumatoid arthritis, ostevathritis and acute
pain. Burk, R. M. et al102 have synthesized interphenylene-7-oxabicyclic[2.2.1]heptane
oxazoles (IV) as prostaglandine F2α antagonists.
Over and above various workers have reported isoxazoles as hypoglycemic103,
linkage for replacement of nucleotide phosphodiester104 and insecticidal agent105.  Some
potent herbicidal activity of isoxazoles found by Reddy et al.106. Some isoxazole deriva-
tives have been patented for their use as herbicides and fungicides107, for the treatment
of prophylaxis of antoimmune or for the treatment inflammatory diseases108, estrogen
receptor modulators109.
The compound [2S-(2α ,  5α ,  6β ) ] -6- [ [ [3- (2-ch lorophenyl ) -5-methy l -4-
isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-car-
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In very recent study Joshi et al.110. synthesized some isoxazole (VI) derivatives
as antitubercular and antimicrobial agents.
As an extension of this study, we wish to report herein a convenient synthesis of
the new isoxazole derivatives bearing 6-chloro cinnolin-4(3H)one moiety which have
been described as under.
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-[(2E)-3-ARYL
PRPO-2-ENOYL]CINNOLIN-4(3H)-ONES.
Chalcone derivatives occupy a unique place in the field of medicinal chemistry
due to wide range of biological activities exhibited by them, prompted by these facts,
the preparation of chalcones of Type (I) have been carried out by condensation of 3-
acetyl-6-chloro cinnolin-4(3H)-one with various aldehydes.
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-












40 %  Alkali
Type-(I) R = Aryl
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Gram positive bacteria : Bacillus megaterium
Bacillus subtillis
Gram negative bacteria : Escherichia coli
Proteus vulgaris
Fungi : Aspergillus niger
Concentration : 40 µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzyl penicillin,
Ampicillin, Norfloxacin,
Griseofulvin
The results of antibacterial screening was compared with standard drugs viz.
Amoxicillin, Benzyl penicillin, Ampicillin, Norfloxacin and the results of antifungal test-
ing was compared with Griseofulvin. The zones of inhibition have been measured in
mm.
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IR SPECTRAL STUDY OF 6-CHLORO-3[(2E)-3-(p-HYDROXY PHENYL)
PROP-2-ENOYL]CINNOLIN-4(3H)-ONE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2927 2975-2950 112
-CH3 C-H str. (sym.) 2854 2880-2860 “
C-H def. (asym.) 1460 1470-1435 “
C-H def. (sym.) 1352 1385-1370 “
Aromatic C-H str. 3033 3080-3030 113
C=C str. 1548 1620-1430 “
C-H i.p. def 1238 1269-1013 “
C-H o.o.p. def.  869   833-660 “
Ether C-O-C str. 1238 1275-1200 112
Carbonyl C=O 1661 1690-1665 “
Vinyl CH=CH str. 3033 3050-3000 113
Halide C-Cl str. 740 750-700 112
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Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of  Proton
1. 3.86 3H singlet Ar-OCH3
2. 6.99 2H double Ar-Ha
(p-disubstitution)
3. 7.26 1H double Vinylic
-CHc=CHd-
4. 7.30 1H double doublet Ar-He
5. 7.49 1H double doublet Ar-Hg
6. 7.50 1H doublet Ar-Hh
7. 7.53 1H singlet Ar-Hf
8. 7.79 1H doublet Vinylic
-CHc=CHd-
9. 8.04 2H double doublet Ar-Hb (p-sub.)
PMR SPECTRAL STUDIES OF 6-CHLORO-3[(2E)-3-(p-METHOXY PHENYL)
PROP-2-ENOYL]CINNOLIN-4(3H)-ONE
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Experimental
SYNTHESIS AND BIOLOGICAL SCREENING 6-CHLORO-3-[(2E)-3-ARYLPROP-
2-ENOYL]CINNOLIN-4(3H)-ONES.
(A) Synthesis of Ethyl 2-[(E)-(4-chlorophenyl)diazenyl]-3-oxobutaroate
4-Chloro aniline (1.28g, 0.01 mol) dissolved in a mixture of con. HCl (15 ml)
and water (15 ml) and cooled to 0 - 5 0C in an ice bath. To this, a cold saturated
solution of sodium nitrite (1.02g, 0.015 mol) was added with constant stirring. The
diazonium salt thus formed was filtered into a cooled solution of ethyl acetoacetate
(1.3g, 0.01 mol) in ethanol (15 ml) and sodium acetate (16.2g, 0.2 mol) in water (250
ml). The solid was collected and recrystallized from methanol. Yield 74%, m.p. 94 0C.
Anal. Calcd. for C12H13ClN2O3 Requires: C, 53.64; H, 4.88; N, 10.43 % Found: C,
53.61; H, 4.87; N, 10.41 %.
(B) Synthesis of 3-Acetyl-6-chlorocinnolin-4(3H)-one
To ethyl 2-[(E)-(4-chlorophenyl)diazenyl]-3-oxobutaroate (3.0g, 0.0112 mol),
anhydrous AlCl3 (2.98g, 0.023 mol) and chlorobenzene (30 ml) was added in order to
dissolve the solids. The mixture was refluxed for 12 hr. Cooled and dilute HCl (25 ml)
was added to it, then heated on a waterbath. After cooling the product was separated
filtered, washed twice with dilute NaOH solution. The product was recrystallized from
methanol. Yield 59 %, m.p. 201 0C. Anal. Calcd. for C10H7ClN2O3 Requires: C, 53.95;
H, 3.17; N, 12.58 % Found: C, 53.91; H, 3.15; N, 12.55 %.
(C) Synthesis of 6-Chloro-3[(2E)-3-(4-methoxyphenyl)prop-2-enoyl]cinnolin-
4-one
Dissolve 3-acetyl-6-chlorocinnolin-4(3H)-one (2.23 g, 0.01 mole) and
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anisaldehyde (1.36 g, 0.01 mol) in dimethyl formamide (30 ml) and was stirred at room
temperature for 24 hr in presence catalytic amount of 40% KOH . The resulting solu-
tion was then poured over crushed ice, the seperated solid was filtered and crystal-
lized from 1,4-dioxane. Yield 68%, m.p. 190 0C. Anal. Calcd. for C18H13ClN2O3 Re-
quires: C, 63.44; H, 3.85; N, 8.22 % Found: C, 63.42; H, 3.84; N, 8.20 %.
Similarly, other compounds were prepared. The physical data are recorded in
Table no. 1.
(D) Biological Screening of 6-Chloro-3[(2E)-3-arylprop-2-enoyl]cinnolin-4-one.
(a)  Antibacterial activity
The purified products were screened for their antibacterial activity using cup-
plate agar diffusion method. The nutrient agar broth prepared by the usual method was
inoculated aseptically with 0.5 ml of 24 hrs. old subcultures of Bacillus megaterium,
Bacillus subtillis, Escherichia coli, Proteus vulgaris in separate conical flask at 40-
50 0C and mixed well by gentle shaking. About 25 ml content of the flask were poured
and evenly spreaded in a petridish (13 cm diameter) and allowed to set for 2 hrs. The
cups (8mm diameter) were formed by the help of borer in agar medium and filled with
0.04 ml (40 µg) solution of sample in DMF.
 The plates were incubated at 37 0C for 24 hrs. and the control was also main-
tained with 0.04 ml of DMF in a similar manner and the zone of inhibition of the bacte-
rial growth were measured in millimeter and recorded in Graphical Chart No. 1.
(b)  Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate agar diffu-
sion method. The culture was maintained on sabourauds agar slants sterilized
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sabourauds agar medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal
spores in a separate flask. About 25 ml of the inoculated medium was evenly spreaded
in a petridish (13 cm diameter) and allowed to set for 2 hrs. The cups (8 mm diameter)
were punched. The plates were incubated at 30 0C for 48 hrs. After the completion of
incubation period, the zone of inhibition in each petridish one cup was filled up with
solvent which acts as control. The zone of inhibition of test solution are recorded in
Graphical Chart No. 1.
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Sr. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
 No. Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
1a C6H5- C17H11ClN2O2 310.73 210 0.563 S1 74 9.02 9.02
1b 3-Br-C6H4- C17H10BrClN2O2 389.63 198 0.527 S1 71 7.19 7.15
1c 2-Cl-C6H4- C17H10Cl2N2O2 345.18 220 0.366 S2 72 8.12 8.11
1d 3-Cl-C6H4- C17H10Cl2N2O2 345.18 174 0.542 S2 65 8.12 8.06
1e 4-Cl-C6H4- C17H10Cl2N2O2 345.18 170 0.538 S2 59 8.12 8.08
1f 3,4-(OCH3)2-C6H4- C19H15ClN2O4 370.78 178 0.543 S1 64 7.56 7.54
1g 4-OCH3-C6H4- C18H13ClN2O3 340.76 190 0.465 S2 68 8.22 8.20
1h 4-SCH3-C6H4- C18H13ClN2O2S 356.83 204 0.450 S2 54 7.85 7.83
1i 3-NO2-C6H4- C17H10ClN3O4 355.73 206 0.556 S2 72 11.81 11.80
1j 2-OH-C6H4- C17H11ClN2O3 326.73 212 0.500 S2 75 8.57 8.54
1k 4-OH-C6H4- C17H11ClN2O3S 326.73 228 0.497 S1 63 8.57 8.52
1l 3-C6H5-O-C6H4- C23H15ClN2O3 402.83 181 0.488 S1 60 6.95 6.94
1m 4-N(CH3)2-C6H4- C19H16ClN3O2 353.80 194 0.528 S1 50 11.88 11.84
TABLE-1:  PHYSICAL CONSTANTS OF 6-CHLORO3-[(2E)-3-ARYLPROP-2-ENOYL]CINNOLIN-4(3H)-
                   ONE




































B.mega 11 12 15 16 12 13 15 12 18 15 14 11 12 20 18 20 21
B.substilis 14 15 11 11 13 12 11 15 13 13 15 14 12 24 17 18 24
P.vulgaris 15 12 11 15 12 15 12 11 15 17 15 17 18 21 25 15 25
E.coli 15 11 13 11 14 14 15 18 15 18 15 14 15 22 24 18 25
A.niger 12 15 17 13 14 15 11 15 12 16 12 14 15 24
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SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(5-
ARYLISOXAZOL-3-YL)-CINNOLIN-4(3H)-ONE.
Isoxazole have been reported to have various pharmacological activities like
antibacterial, antifungal, insecticidal etc. In order to achieving better drug potency, we
have prepared isoxazole derivatives of Type-(II) by the cyclo condensation of 6-chloro-
3-[(2E)-3-arylprop-2-enoyl]cinnolin-4(3H)-one of Type-(I) with hydroxylamine hydrochlo-
ride in presence of sodium acetate in glacial acetic acid.
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-
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IR SPECTRAL STUDY OF 6-CHLORO-3-(5- (p-METHOXY PHENYL)
ISOXAZOL-3-YL)-CINNOLIN-4(3H)-ONE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2923 2975-2950 112
-OCH3 C-H str. (sym.) 2840 2880-2860 “
C-H def. (asym.) 1454 1470-1435 “
C-H def. (sym.) 1381 1385-1370 “
Aromatic C-H str. 3087 3080-3030 113
C=C str. 1544-1454 1620-1430 “
C-H i.p. def 1247 1269-1013 “
C-H o.o.p. def.   678   833-660 “
Isoxazole C=C str. 1575 1580-1500 112
C=N str. 1454 1470-1460 “
N-O str.   823 850-810 “
Ether C-O-C 1247 1260-1200 113
1041 1075-1020 “
Halide C-Cl str. 740 750-700 112
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Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of  Proton
1. 3.88 3H singlet Ar-OCH3
2. 6.98 2H double Ar-Ha
(p-disubstitution)
3. 7.30 1H double doublet Ar-Hd
4. 7.51 1H singlet Ar-Hg
5. 7.53 1H doublet Ar-He
6. 7.68 1H singlet Ar-Hf
7. 7.79 1H singlet Ar-Hc
(isoxazole ring)
8. 8.04 2H double doublet Ar-Hb (p-sub.)
PMR SPECTRAL STUDIES OF 6-CHLORO-3-(5-(p-METHOXY PHENYL)
ISOXAZOL-3-YL)-CINNOLIN-4(3H)-ONE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(5-
ARYLISOXAZOL-3-YL)-CINNOLIN-4(3H)-ONE
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of 6-Chloro-3-(5-(4-methoxyphenyl)isoxazol-3-yl)-cinnolin-
4(3H)-one
6-Chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-one (3.4 gm,
0.01 mol) in dioxane and anhydrous sodium acetate (0.73gm, 0.01 mol) dissolved in
minimum amount of acetic acid was added to a solution of hydroxylamine hydrochlo-
ride. The reaction mixture was refluxed on oil bath for 10-12 hrs. The product was
isolated and crystallized from ethanol. Yield 51 %, m.p. 200 0C Anal. Calcd. for
C18H12ClN3O3 Requires: C, 61.11; H, 3.42; N, 11.88 % Found: C, 61.10; H, 3.40, N,
11.84 %.
Similarly, other 6-chloro-3-(5-arylisoxazol-3-yl)cinnolin-4(3H)-ones. The physi-
cal data are recorded in Table No. 2.
(C) Biological screening of 6-Chloro-3-[5-arylisoxazol-3-yl]cinnolin-4(3H)-one
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The
zones of inhibition of test solution are reported in Graphical Chart No. 2.
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B.mega 14 15 12 14 13 10 18 15 13 17 20 18 20 21
B.substilis 13 12 10 15 19 13 14 16 15 17 24 17 18 24
P.vulgaris 18 12 13 18 19 17 13 15 12 18 21 25 15 25
E.coli 18 14 14 16 13 15 14 17 14 14 22 24 18 25
A.niger 11 15 16 12 14 16 18 12 13 14 24
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The chemistry of pyrazoline was reviewed by Jarobe in 1967. Pyrazoline has
three possible tautomeric structures, but the structure shown is the most stable, which
can be prepared by the reaction of hydrazine hydrate with acrolein.
2-Pyrazoline consist a unique class of  five membered nitrogen heterocycle.
During the past years considerable evidence has been accumulated to demonstrate
the importance of 2-pyrazoline derivatives. There has been considerable interest in
the pyrazoline ring system both with regard to heterocyclic chemistry and the pharma-
cological activities of several of its derivatives.
SYNTHETIC ASPECT
Different methods are available in literature for the preparation of 2-pyrazoline.
The popular methods are:
1. Among the methods employed in synthesis of pyrazolines, condensation of a
variety of substituted chalcones with hydrazine and its derivatives is commonly
used1,2,3.











3. Epoxydation of chalcones gave epoxy ketones which on reaction with pyrazoline
or phenyl pyrazoline to give substituted pyrazoline derivatives5.
4. Dipolar cycloaddition of nitrilamines to dimethyl fumarate, fumaro nitrile and the
N-aryl maleimides yields the corresponding pyrazolines6.
5. 2-Pyrazolines can also be obtained through cycloaddition of diazomethane to
appropriately substituted chalcones7.
Recenlty, microwave assisted synthesis of 2-pyrazolines described  by S. Paul
et al.8 and Dandia Anshu et al.9.
REACTION MECHANISM
The following mechanism seems to be operable for the condensation for the
chalcone with hydrazine derivative10.
THERAPEUTIC IMPORTANCE























































An interesting activity of various substituted pyrazolines as biological agents have
attracted considerable attention. The pharmaceutical importance of these compounds
lies in the fact that they can be effectively utilized as antibacterial, antifungal, antiviral,
antiparasitic, antitubercular, incecticidal21-26 agent. Some of these compounds have also
ant i inf lammatory,  ant id iabet ic,  anesthet ic and analgesic propert ies27-30.  In
addition,pyrazolines have played a crucial part in the development of theory in hetero-
cyclic chemistry and also used extensively in organic synthesis31-35.
Davood azarifar36 have synthesized some new 3,5-dinaphthyl substituted 2-
pyrazolines (I) and studied their antimicrobial activity. Dashi and Kadu37 have recently
reported the synthesis and antimicrobial activity of naphthyl substituted  2-pyrazoline.
Clinton, R. O. et al.38 also synthesized some pyrazoline derivatives as bacteriostatic,
fungicidal and anticancer agents.
Recently O. M. Abdel Hafez et al.39 have prepared some potentially bioactive
pyrazoline derivatives (II) from visnaginone. Nauduri D et al.40 synthesized 2-pyrazoline
derivatives and tested for antibacterials and antimycotics activity. Palaska E et al.41
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have synthesised and reported some 3,4-diphenyl-2-pyrazolines as antidepressant
agents.
Sr ivastava et  a l . 42 have synthesized 1-acety l -5-ary l idenyl -3-(2 ’ -oxo/
thiobarbiturinyl)-2-pyrazolines and reported it as anticonvulsant agents. Holla, B et al.43
prepared some fluorine containing arylfuryl-N-phenylpyrazolines (III) for antibacterial
activity. Chan-DMT et al.44 have described N-substituted pyrazoline type insecticides.
Tanka Katsuhori45 have patented pyrazoline as herbicides.
Furthermore, Sonare S. S. et al.46 have synthesized 3-(2’-acetixy-4’-
methoxyphenyl)-5-(substituted phenyl)-pyrazoline and tested their antimicrobial activ-
ity. Balakrishana Kalluraya and co-workers47 have reported 1-aryl acetyl-3-(5’-nitro-2’-
thienyl)-5-aryl-5-hydroxy pyrazoline as antifungal agent. Gieninah, Magdy et al.48 pre-
pared 6-,7-and 8-(5-aryl-1-phenyl-2-pyrazolin-3-yl) imidazo and pyrimidi[2,1-
































Some novel pyrazoline containing bisphosphonate ester (V) was synthesized and re-
ported as antiinflammatory and antiarithritic agents by Nugent Richard A et al.49. In
continuation of our work on pyrazoline derivatives (VI) Joshi et al.50 prepared some
anticancer, antitubercular and antimicrobial agents.
Therefore,as a part of our program focused on 2-pyrazolines with biological
activity, and in connection with our interest in the chemistry of arylated pyrazolines,in
this part we report the synthesis and antimicrobial properties of some new 2-pyrazolines
containing 6-chloro cinnolin-4(3H)-one moiety. The synthesis and therapeutic evalua-
tion of them, have been described as under.
SECTION-I: Synthesis and biological screening of 3-(1-Acetyl-5-aryl-4,5-dihydro-
1H-pyrazol-3-yl)cinnolin-4(3H)-one























SYNTHESIS AND BIOLOGICAL SCREENING OF 3-[1-ACETYL-5-ARYL-4,5-
DIHYDRO-1H-PYRAZOL-3-YL]-6-CHLOROCINNOLIN-4(3H)-ONE
Pyrazolines as a class of heterocyclic compounds have been studied extensively
for the past several years. They are associated with broad spectrum of biological ac-
tivities like anticancer, anticonvulsant, insecticidal, antipyratic etc. Keeping in view of
these diversified biological activities, we have undertaken the synthesis of some new
pyrazoline derivatives possessing better biological activity which have been described
as under. We have synthesized 3-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazol-3-yl]-6-chlorocinnolin-4(3H)-one of Type-(III) by the condensation of hydrazine
hydrate with chalcones of Type-(I).
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-
















Type-(III) R = Aryl
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IR SPECTRAL STUDY OF 3-[1-ACETYL-5-PHENYL-4,5-DIHYDRO-1H-
PYRAZOL-3-YL]-6-CHLORO CINNOLIN-4(3H)-ONE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2923 2975-2950 51
-CH3 C-H str. (sym.) 2852 2880-2860 “
C-H def. (asym.) 1452 1470-1435 “
C-H def. (sym.) 1373 1385-1370 “
Aromatic C-H str. 3060 3080-3030 52
C=C str. 1485 1620-1430 “
C-H i.p. def 1068 1269-1013 “
C-H o.o.p. def.  873   833-660 “
Ether C-O-C str. 1244 1275-1200 51
Pyrazoline C=O 1668 1690-1665 “
C=N str. 3033 3050-3000 52
Halide C-Cl str. 771 750-700 51















































Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 2.4 3H singlet -C(=O)CH3
2. 3.01 1H double doublet -C-Hc
3. 3.72 1H double duoblet -CHd
4. 3.84 3H singlet Ar-OCH3
5. 5.54 1H double doublet -CHe
6. 6.9 2H doublet Ar-Ha (p-sub.)
7. 7.11 1H singlet Ar-Hf
8. 7.18 1H doublet Ar-Hi
9. 7.22 1H singlet Ar-Hg
10. 7.26 1H double doublet Ar-Hh
11. 7.68 2H doublet Ar-Hb (p-sub.)
PMR SPECTRAL STUDIES OF 3-[1-ACETYL-5-(4-METHOXY PHENYL)-4,5-
DIHYDRO-1H-PYRAZOL-3-YL]-6-CHLORO CINNOLIN-4(3H)-ONE











































SYNTHESIS AND BIOLOGICAL SCREENING OF 3-[1-ACETYL-5-ARYL-4,5-
DIHYDRO-1H-PYRAZOL-3-YL]-6-CHLOROCINNOLIN -4-(3H)-ONE
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4-(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of 3-[1-Acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-
yl]-6-chlorocinnolin-4(3H)-one
A mixture of 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-
one (3.4 gm, 0.01 mol) in glacial acetic acid (25 ml) and hydrazine hydrate (0.5gm,
0.01 mol) was refluxed for 8 hrs. The resulting mixture was poured onto crushed ice.
The product was isolated and crystallized from ethanol. Yield 53 % m. p. 1860C, Anal.
Calcd. for C20H17ClN4O3 Requires: C, 60.53; H, 4.32; N, 14.12 % Found: C, 60.50;
H, 4.31; N, 14.11 %.
Similarly, other 3-[1-acetyl-5-aryl-4,5-dihydro-1H-pyrazol-3-yl]-6-chlorocinnolin-
4(3H)-ones were prepared. The physical data are recorded in Table No. 3.
(C) Biological screening of 3-[1-Acetyl-5-aryl-4,5-dihydro-1H-pyrazol-3-yl]-6-
chlorocinnolin-4(3H)-one
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The






































































































































































































































































































































































































































































































































































   
   
   
   












































































B.mega 17 19 14 12 15 10 18 12 16 16 20 18 20 21
B.substilis 16 21 12 15 14 11 14 11 18 14 24 17 18 24
P.vulgaris 16 20 16 17 17 13 16 13 15 14 21 25 15 25
E.coli 18 16 16 14 12 14 20 17 17 15 22 24 18 25
A.niger 19 17 15 24 17 18 19 17 14 12 24















SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-[5-ARYL-1-PHE-
NYL-4,5-DIHYDRO-1H-PYRAZOL-3-YL]CINNOLIN-4(3H)-ONE
Pyrazolines have been found to be associated with broad spectrum of biologi-
cal activities. Hence, it was thought of interest to synthesize 6-chloro-3-[5-aryl-1-phe-
nyl-4,5-dihydro-1H-pyrazol-3-yl]cinnolin-4(3H)-ones of Type (IV) from 6-chloro-3-[(2E)-
3-aryl-prop-2-enoyl]cinnolin-4(3H)-ones of Type (I) by the cyclocondensation with phe-
nyl hydrazine shown as under.
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectros-
copy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-












IR SPECTRAL STUDY OF 6-CHLORO-3-[1,5-DIPHENYL-4,5-DIHYDRO-1H-
PYRAZOL-3-YL]CINNOLIN-4(3H)-ONE












































Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2952 2975-2950 50
-CH3 C-H str. (sym.) 2856 2880-2860 “
C-H def. (asym.) 1411 1470-1435 “
C-H def. (sym.) 1334 1385-1370 “
Aromatic C-H str. 3049 3080-3030 51
C=C str. 1490 1620-1430 “
C-H i.p. def 1060 1269-1013 “
C-H o.o.p. def.  844   833-660 “
C=O 1660 1725-1650 50
Pyrazoline C=N str. 1633 1627-158 51
Halide C-Cl str.   746 750-700 50
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PMR SPECTRAL STUDIES OF 6-CHLORO-3-[5-(4-METHOXYPHENYL)-1-
PHENYL-4,5-DIHYDRO-1H-PYRAZOL-3-YL]CINNOLIN-4(3H)-ONE










Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 2.97 1H double doublet -C-Hc
3. 3.72 1H double duoblet -CHd
4. 3.81 3H singlet Ar-OCH3
5. 5.21 1H double doublet -CHe
6. 6.93 2H doublet Ar-Ha (p-sub.)
7. 7.11 1H singlet Ar-Hf
8. 7.18 1H doublet Ar-Hi
9. 7.22 1H singlet Ar-Hg
10. 7.26 2H doublet Ar-Hh
11. 7.63 2H doublet Ar-Hb (p-sub.)
































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-[5-ARYL-1-PHE-
NYL-4,5-DIHYDRO-1H-PYRAZOL-3-YL]CINNOLIN - 4(3H)-ONE
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of 6-Chloro-3-[5-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-
pyrazol-3-yl]cinnolin-4(3H)-one
A mixture of 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-
one (3.4 gm, 0.01 mol) in alcohol (25 ml) and phenyl hydrazine (0.92gm, 0.01 mol) was
refluxed for 8 hrs. The resulting mixture was poured on crushed ice. The product was
isolated and crystallized from ethanol. Yield 60 % m. p. 1400C, Anal. Calcd. for
C18H13ClN2O3 Requires: C, 66.90; H, 4.44; N, 13.00 % Found: C, 66.87; H, 4.43; N,
12.98 %.
Similarly, other 6-chloro-3-[5-aryl-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]cinnolin-
4(3H)-one were prepared. The physical data are recorded in Table No. 3.
(C) Biological screening of 6-Chloro-3-[5-aryl-1-phenyl-4,5-dihydro-1H-
pyrazol-3-yl]cinnolin-4(3H)-one
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The
































































































































































































































































































































































































































































   
   
   
   












































































































B.mega 16 15 16 17 17 14 18 17 15 14 20 18 20 21
B.substilis 13 18 14 17 17 16 16 14 18 15 24 17 18 24
P.vulgaris 11 22 18 23 23 24 23 22 24 22 21 25 15 25
E.coli 12 14 12 16 16 16 15 14 14 14 22 24 18 25
A.niger 24 18 20 20 20 17 15 19 16 16 24
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Introduction
Pyridine, which belong to an important group of heterocyclic compounds has
been explored extensively for their applications in the field of medicine1, agriculture
and industrial chemistry. Pyridine-3-carboxamide occurs as a component of the struc-
ture of the important coenzymes NADP+(a), one of the B2 complex of Vitamins, oc-
curs in red blood corpuscles and participates in biochemical redox reaction. Pyridoxol
(Vitamin B6)(b), occurs in yeast and wheatgerm is an important food additive.
The availability of 3-cyano pyridine, nicotinamide and nicotic acid make pos-
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SYNTHETIC ASPECT
Different methods for preparation of 3-cyanopyridines documented in literature
some of them are as follows:
1. 3-Cyanopyridine can be prepared by the vapour phase air oxidation of nicotine
over V2O52 or alkenyl substituted pyridines in presence of ammonia3.
2. Oxley and co-workers4 synthesized pyridine benzenesulphonate by heating nico-
tinic acid, benzenesulphonate and PhSO2NH2 at 2300 for 40 minutes.
3. Samour and co-workers prepared substituted cyanopyridines by the condensa-
tion of chalcone with ethyl cyanoacetate and malononitrile in presence of  am-
monium acetate5,6.
4. A. Sakuri and Midorikawa have reported that malononitrile reacts with α,β-un-
saturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines7,8.
5. Cyanopyridine derivatives (I) are obtained by reaction of R-CO-CH3 with 2-
cyanothioacetamide in presence of N-methyl morpholine, have been reported
by Dayachenko V. D.9, and cyanopyridine derivatives (II) reported by Metwally
Nadia et al.10.
6.  Quiroya Jairo and co-workers have synthesized pyrido-[2,3-d]-pyrimidin-4(3H)-
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7. Dornow and Neuse12 synthesized substituted 3-cyano-pyridine by boiling
ethyl cyanoacetate and ethyl acetoacetate with ammonia.
REACTION MECHANISM
The reaction proceeds through conjugated addition of active methylene com-
pounds to the α,β-unsaturated system as shown below.
THERAPEUTIC INTEREST
Cyano pyridine derivatives have been found to posses range of therapeutic
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Recently, Villhauer, Edwin B. et.al.25 reported the derivatives of cyano pyridine
(I) as antihyperglycemic agent. K. Kadlec and Hanslian26 showed that 2-methyl-3-nitro-
4-methoxy-5-cyano-6-chloropyridines caused occupational eczema in Vitamin-B6
factoty workers. Rigternik and Raymond27 studied the pesticidal activity of 3-cyano-
pyridine derivatives. W. Hoefling and co-workers28 prepared 3- and 4-cyanopyridines,
which possess tuberculosis arresting properties.
Moreover, Harada, Hiroki et al.29 synthesized 2-acylamino-3,5-dicyanopyridine
derivatives (II) as high conductance type calcium sensitivity K channel opening drugs.
Barton et al.30 prepared 2-substituted-3-cyano-5-nitropyridines which possess fungi-
cidal and insecticidal properties. Kurt et al.31 studied the antiphlogistic and analgesic
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Furthermore, Nantermet, Philippe G. et al.32 also prepared pyridinyl aminoamides
(III) as thrombin inhibitors. Manna Fedele and co-workers33 have reported some 3-
cyano pyridines as antiinflammatiry agents. Villa lobas Anabella et al.34 have prepared
some new 3-cyanopyridines and reported them as choline-stearase inhibitors.
Abd El-Galil and E. Amr35 prepared cyanopyridine derivatives (V) and screened
for their antimicrobial activity. Umed-Ten and co-workers36 prepared cyanopyridines
as potent fungicides. Some novel cyanopyridines synthesized and reported as
fungcidal37, insecticidal38 and herbicidal39. Some investigator have studied as antimi-
crobial agent40 and studied bacteriostatic effect41,42,43.
Furthermore cyanopyridines are also found applicable in the dying of polyester
and acrylic fiber44. The oxide activator bleaching activity of cyanopyridine has been
proved by Rees Wayne M.45.Moreover, Oshida Mario46 have constructed some new
cyanopyridine derivatives which inhibit ceberal edema and delayed neuron death.
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Joshi et al47. recently have synthesized some new cyano pyridine (VI) derivatives
as anticancer and antimicrobial agents.
Keeping these observations in view and in continuation of our work on the syn-
thesis of cyanopyridine heterocyclec, it was contemplated to synthesize a new series of
cyanopyridine containing 6-chloro cinnolin-4(3H)-one moiety.
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-4-ARYL-6-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLIN-3-YL)NICOTINONITRILE.
In recent years, much interest has been focused on the synthesis of pyridines as
the pyridine ring system is associated with valuable pharmacological activity like anti-
bacterial, antimalarial, antihypertensive, antifungal, anticonvulsant etc. Considering
these facts we thought it is worthwhile to synthesize some novel derivatives in asso-
ciation with cinnoline nucleus in search of better potential drugs. Cyanopyridine de-
rivatives of Type-(V) have been synthesized by the reaction of the chalcones of the
Type-(I) with malononitrile in presence of ammonium acetate.
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-
















Type-(V) R = Aryl
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IR SPECTRAL STUDY OF 2-AMINO-4-(4-METHOXY PHENYL)-6-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLIN-3-YL)NICOTINONITRILE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2923 2975-2950 48
-CH3 C-H str. (sym.) 2850 2880-2860 “
C-H def. (asym.) 1442 1470-1435 “
C-H def. (sym.) 1361 1385-1370 “
Aromatic C-H str. 3033 3080-3030 49
C=C str. 1479 1620-1430 “
C-H i.p. def 1282 1269-1013 “
C-H o.o.p. def.  835   833-660 “
Ether C-O-C str. 1249 1275-1200 48
Pyridine C=C str. 1622 1650-1520 49
C=N str. 1573 1580-1550 “
Nitrile C=N str. 2202 2240-2120 “
Halide C-Cl str. 744 750-700 48
Amino NH2- str. 3452, 3330 3550-3250 49
1573 1650-1550 “
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Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 3.87 3H singlet Ar-OCH3
2. 6.98 2H doublet Ar-Ha (p-sub.)
3. 7.31 1H singlet Ar-Hd
4. 7.36 1H duoblet Ar-Hf
5. 7.56 1H singlet Ar-He
6. 7.63 1H doublet Ar-Hg
7. 7.75 1H singlet Ar-Hc (pyridine)
8. 8.03 2H doublet Ar-Hb (p-sub.)
PMR SPECTRAL STUDIES OF 2-AMINO-4-ARYL-6-(6-CHLORO-4-OXO-3,4-
DIHYDROCINNOLIN-3-YL)NICOTINONITRILE
















96S tud i e s  on  Heterocyc l i c  . . .







97S tud i e s  on  Heterocyc l i c  . . .
C y a n o p y r i d i n e s . . .
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-4-ARYL-6-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLIN-3-YL)NICOTINONITRILE
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of 2-Amino-4-(4-methoxyphenyl)-6-(6-chloro-4-oxo-3,4-
dihydrocinnolin-3-yl)nicotinonitrile.
To a solution of 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-
4(3H)-one (3.4 gm, 0.01 mol) in dioxane, malononitrile (1.29g, 0.01 mol) and ammo-
nium acetate (9.24 g, 0.12 mol) was added and refluxed on oil bath for 12 hr. The
reaction mixture was cooled and poured over crushed ice. The product was isolated
and crystallized from toluene. Yield 53 %, m.p. 206 0C Anal. Calcd. for C21H14ClN5O2
Requires: C, 62.46; H, 3.49; N, 17.34 % Found: C, 62.43; H, 3.47, N, 17.33 %.
Similarly, other 2-amino-4-aryl-6-(6-chloro-4-oxo-3,4-dihydrocinnolin-3-
yl)nicotinonitrile. The physical data are recorded in Table No. 5.
(C) Biological  screening of  2-Amino-4-aryl -6- (6-chloro-4-oxo-3,4-
dihydrocinnolin-3-yl)nicotinonitrile
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The
zones of inhibition of test solution are reported in Graphical Chart No. 5.
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B.mega 15 14 14 15 17 17 14 19 18 17 20 18 20 21
B.substilis 16 15 15 14 13 16 19 17 15 21 24 17 18 24
P.vulgaris 18 22 23 24 25 24 21 22 22 18 21 25 15 25
E.coli 15 14 12 16 13 11 14 15 18 19 22 24 18 25
A.niger 18 19 21 20 18 18 19 18 18 16 24
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Pyridones, which belongs to an group of nitrogen containing heterocyclic com-
pounds have been extensively explored for their application in the field of medicine. In
recent years, pyridones with a carbonyl group at position 2 (I), have attracted consid-
erable attention as they are endowed with wide range of activities. Numerous reports
have appeared in the literature which focused their chemistry and applications.
Some 2-pyridones are physiologically as well as pharmacologically important

























Various methods are documented in literature for preparation of 2-pyridones,
which are as under.
(i) S. A. harris and K. Folkers1 have prepared 3-cyano-2-pyridone by the condensa-
tion of cyanoacetamide with 1,3-diketone or β-keto ester.
(ii) M. A. Sluyter et al.2 have prepared fused 2-pyridones.
(iii) G. Simchen and G. Entemmann3 have synthesized 2-pyridone in which the ring
nitrogen comes from a nitrile group in acyclic precursor, addition of HCl to the
nitrile produces an imidoyl chloride which can cyclize.
REACTION MECHANISM
The addition reaction between ethyl cyano acetate and α,β-unsaturated ketone
give cyano pyridone via Michael addition. Here α,β-unsaturated compound is known
as acceptors and active –CH group containing compound known as addendam. It in-































































Literature survey reveals that various pyridones having potential of drugs are











Moreover, several co-workers have pre reported 2-pyridones as S3 site of throm-
bin inhibitors14, herbicidal15, SH2 domain inhibitor16 and GABA-A receptor17. Peter et
al.18 have prepared pyridinyl methyl substituted pyridines and pyridones as angiotensin
II antagonists. H. Posnes19 reported 2-pyridones as physiologically active compounds.











Mukhtar Hussain Khan and co-workers21-22 have synthesized 2-pyridone deriva-
tives (II) and (III) which possess insecticidal and pesticidal activity. E. Amer23 prepared
3-cyano-2-pyridone derivatives displaying high antimicrobial activity. Abou El-Fotooh
et al.24 have demonstrated pyridones as anticancer agents. F. Paila25 synthesized 2-
pyridone derivatives showing good cardiotonic activity.
Furthermore, Stenzel, Wolfgang et al.26 reported some pyridone derivatives (IV)
as cardiotonic, hypnotics, antiasthematics and antithrombotic. Fischer Reiner et al.27















































Gulcan Ozturk et al.28 prepared 1,2,5-substituted-4-pyridone derivatives having
analgesic and antiinflammatory activity. Tanaka A. and co-workers29 prepared 2-
pyridone derivatives, which showed adenosine antagonist activity and anticatalepsy
activity.
Thus, significant biological properties associated with pyridones have aroused
considerable interest to design the compounds with a view to get better drug potential
to study their pharmacological profile, which have been described as under.






SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-6-(6-CHLORO-4-OXO-
3,4-DIHYDROCINNOLIN-3-YL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONITRILE.
Compounds containing pyridine ring are widely distributed in nature. Many
pyridone derivatives are reported to associated with valuable pharmacological activity
like antibacterial, antimalarial, antihypertensive, antifungal, anticonvulsant etc. Con-
sidering these facts we thought it is worthwhile to synthesize some novel derivatives in
association with cinnoline nucleus in search of better potential drugs. Nicotinonitrile
derivatives of Type-(VI) have been synthesis of the chalcones  of the Type-(I) with ethyl
cyanoacetate in presence of ammonium acetate.
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concen tration of 40 µg/ml. The bio-




















IR SPECTRAL STUDY OF 4-(4-METHOXY PHENYL)-6-(6-CHLORO-4-OXO-
3 , 4 - D I H Y D R O C I N N O L I N - 3 - Y L ) - 2 - O X O - 1 , 2 - D I H Y D R O P Y R I D I N E - 3 -
CARBONITRILE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2943 2975-2950 47
-CH3 C-H str. (sym.) 2906 2880-2860 “
C-H def. (asym.) 1438 1470-1435 “
C-H def. (sym.) 1375 1385-1370 “
Aromatic C-H str. 3033 3080-3030 48
C=C str. 1479 1620-1430 “
C-H i.p. def 1276 1269-1013 “
C-H o.o.p. def.  839   833-660 “
Ether C-O-C str. 1226 1275-1200 47
Pyridone C=O str. 1712 1650-1520 48
Nitrile C=N str. 2210 2240-2120 “
N - H str. 3406 3450-3200 “
N-H str. 1610 1650-1580 “
Halide C-Cl str. 744 750-700 47





























































Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 3.86 3H singlet Ar-OCH3
2. 6.99 2H doublet Ar-Ha (p-sub.)
3. 7.34 1H singlet Ar-Hd
4. 7.69 1H singlet Ar-Hc
5. 7.91 1H singlet Ar-He
6. 7.96 1H doublet Ar-Hf
7. 8.92 2H doublet Ar-Hb (p-sub.)
PMR SPECTRAL STUDIES OF 4-(4-METHOXY PHENYL)-6-(6-CHLORO-4-
OXO-3,4-DIHYDROCINNOLIN-3-YL)-2-OXO-1,2-DIHYDROPYRIDINE-3-
CARBONITRILE




































SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-6-(6-CHLORO-4-OXO-
3,4-DIHYDROCINNOLIN-3-YL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of 4-(Methoxy phenyl)-6-(6-chloro-4-oxo-3,4-dihydrocinnolin-
3-yl)-2-oxo-1,2-dihydropyridine-3-carbonotrile.
A mixture of 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-
one (3.4 gm, 0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 mol) in presence of ammo-
nium acetate (9.24 g, 0.12 mol) dissolve in dioxane was refluxed on oil bath for 12 hrs.
The reaction mixture was cooled and poured over crushed ice. The product was iso-
lated and crystallized from toluene. Yield 55 %, m.p. 180 0C Anal. Calcd. for
C18H12ClN3O3 Requires: C, 62.31; H, 3.24; N, 13.84 % Found: C, 62.30; H, 3.21, N,
13.81 %.
Similarly, other 4-Aryl-6-(6-chloro-4-oxo-3,4-dihydrocinnolin-3-yl)-2-oxo-1,2-
dihydropyridine-3-carbonotrile. The physical data are recorded in Table No. 6.
(C) Biological screening of 4-Aryl-6-(6-chloro-4-oxo-3,4-dihydrocinnolin-3-yl)-
2-oxo-1,2-dihydropyridine-3-carbonotrile
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The

































































































































































































































































































































































































































































   
   
   
   

























































































































B.mega 16 19 15 16 20 15 16 14 11 12 20 18 20 21
B.substilis 16 14 15 17 13 25 14 15 24 16 24 17 18 24
P.vulgaris 25 18 24 24 25 14 22 23 12 12 21 25 15 25
E.coli 14 16 15 17 13 20 14 13 16 10 22 24 18 25
A.niger 16 16 18 20 18 18 19 20 18 22 24
















1. S. A. Harris and K. Folfers; J. Am. Chem. Soc., 61, 1245 (1939).
2. M. A. Sluyter, U. K. Pandit, W. N. Speckamp and H. O. Hulsman; Tetrahedron Lett. 87 (1996).
3. G. Simchen and G. Entenmann; Angew. Chem. Int. Edn. Engl., 12, 119 (1973).
4. Hu Zhiyong, Wang Huical; Chem. Abstr., 119, 72465d (1993).
5. Erol D. D., Yulung N. and Ankara Turk; Eur. J. Med. Chem. 29(11), 893-897 (1994); Chem. Abstr.,
122, 13650u (1995).
6. Hartann R. W., Reichert N. and Grzhrinh S.; Eur. J. Med. Chem., 29(11), 807-817 (1994); Chem.
Abstr., 122, 239500n (1995).
7. Peter Fay, Han Ko, Rudolf Huebsch Walter and Kraemer Thomas; Eur. Pat. Appl. Ep., 62, 3611 (Cl.
CO7D 401/12); Chem. Abstr., 122, 55897r (1995).
8. Uekawa Taru, Takemura Susumu, Enomato Masayuki and Sakaki Ma Saharu; Pat. Appl. EP.
488,220 (Cl. CO7D 413/04) (1992); Chem. Abstr., 118, 80944d (1993).
9. Rosenstock Bernd, Peyman Anu Schirwan, Ruppert Dieter, Riess Guenther; PCT Int. Appl. WO 96
30,342 (Cl. CO7D 213/89); Chem. Abstr., 126, 7993e (1997).
10. Iamail Abdel Hamid, H. Mohammed; Chem. Abstr., 126, 330573g (1997).
11. Shivkumar B. and Margund L. G.; Indian J. Heterocycl. Chem., 8(1), 27-36 (1998); Chem. Abstr.,
130, 66428e (1999).
12. Essawy, A.; Younes, M. El-GArby; Badran, M. M.; Heikle, A. Z. M. Rev. Roum. Chim. 1981, 16(2),
245-52 (Eng); Chem. Abstr., 95, 150488r (1980).
13. Al-Omran, Featima; Elassar, Abdel-Zaher A.; El-Khair, Adel A. Tetrehedron 2001, 57 (51), 10163-
10170; Chem. Abstr., 136, 309834a (2002).
14. Reiner John E., Lim Wilby, Margeu Rita S., Bruncj Terence K. and Ha-Vong Theresa; Chem. Lett.,
9(6), 895-900 (1999); Chem. Abstr., 131, 286379a (1999).
15. Yamagudi Mikio, Ito Voshiniro, Shibaytama Atsushi, Yomaji, Mitsuhiro and Hanai Rgo; Jpn. Kokai
Tokkyo Koho JP 11 140,054 (Cl. CO7D 213/64) ; Chem. Abstr., 131, 44738a (1999).
16. Betageri Rajashekhar, Beaulieu Llinas Brunet, Pierrel; PCT Int. Appl. WO 99 31,066 (Cl. CO7D 213/
75); Chem Abstr., 131, 59136a (1999).
17. Harison  Timothy, Moyes Christopher, Richard Laewis, Richard Thomas; PCT Int. Appl. WO 98
10,384 (Cl. CO7D 471/14); Chem. Abstr., 130, 13918h (1999).
18. Peter Fey, Dressel Juergem, Kanko Rudolf, Huebsch Walter and Kraemer Thomas; Eur. Pat. Appl.
EP 62 3611 (Cl. CO7D 401/14); Chem. Abstr., 122, 55897x (1995).




20. Devdas, Balekudru; Walker, John; Selnes, Shaun R.; Boehm, Terril.; Durley, Richard C.; Devraj,
Rajesh; Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.; Madsen, Heather M.; Alvira Edgardo;
Promo, Michale A.; Blevis-Bal, Radhika M.; Marrfo, Laura D.; Hitchcoke, Jeff; Owen, Thomas;
Nang, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; et al. PCT Int. Appl. WO 03 68, 230 (Cl.
A61K31/4412), 21 Aug 2003, US Appl. PU 436,915, 30 Dec 2002; 1052 pp.
21. Mukhtar Hussain Khan, Raizul Haque and Nizamuddin; Indian J. Chem., 38(B), 452-456 (1999).
22. Mukhtar Hussain Khan, Raizul Haque, Taruna Agrawal and Nizamuddin; Indian J. Chem., 38(B),
452-456 (1999).
23. Abd El-Galil and E. Amer; Indian J. Chem., 40(B), 213-221 (2001).
24. Abou El-Fotooh, G. Hamman, Mohie A. Sharaf and Nagalla A. Abd El-Hafeza; Indian J. Heterocycl.
Chem., 10, 49 (2000).
25. Fossa Paila, Mosti Luisa; Menozzi Giulia, Manetti Fabrizio, Darigo Paoda, Floreani Maura; Med.
Chem. Research, 11(3), 137-152 (2002); Chem. Abstr., 137, 369943e (2002).
26. Stenzel, Wolfgang; Hofferber, Eva. Eur. Pat. Appl. E.P. 167,121 (Cl. CO7D213/85), 08 Jan 1986,
DE Appl. 3,424,685, 05 Jul 1984; 26 pp.
27. Fischer, einer; Ullmann, Astrid; Trautwein, Axel; Drewes, Mark-Wilhelm; Erdelen, Christoph;
Dahmen, Peter; Feucht, Dieter; Pontzen, Rolf; Loesel, Peter. Der. Offen. DE 10, 100,175 (Cl.
C07D417/04), 11 Jul 2002.
28. Gulcan Ozturk, Dilek Demir Eral, Mutlu Dilsiz Aytermir, Tayfun Uzbay; Eur. J. Med. Chem., 37,
829-834 (2002).
29. Tanaka Akira; Minagawa Masatoshi, Akahane Atsushi; Chem. Abstr., 139, 22210j (2003).
30. A Handbook of spectroscopic data by B. D. Mishtry, 1st ed. ABD Press Jaipur 11-36 (2000);  “Absorp-
tion spectroscopy data of organic compounds”, by V. M. Parikh, Addision-Wesley pub. Co., London,
243-258 (1978).
31. Introcuction to Infrared and Raman spectroscopy by Norman B. Colhup, Lowrence H. Daly and





Pyran derivatives are associated with wide range of applications in various fields
like pharmaceutical, dyes, insecticides and sweet smelling substances. Pyran ring
system also occurs in nature abundantly such as in large number of natural coloured
compounds, in vitamine E, in cloves, in fish poisons, in certain alkaloids and other
substances.
Pyran are six member doubly unsaturated compounds containing one oxygen
atom in the ring. The double bonds may be conjugated known as α- or 1,2-pyran or it
may be isolated known as γ-or 1,4-pyran.
SYNTHETIC ASPECT
Various methods for the preparation of pyran derivatives have been cited in the
literature1-10.
1. Reaction between α,β- unsaturated carbonyl system with malononitrile led to
correspnding 2-amino-3-cyano-4H-pyran11.
2. Elssar A. Z. et al12 prepared 3-cyano-pyran derivatives by the reaction of α-









3. Abdel-Ghany H. et al.13 have been synthesized cyano derivatives by the reac-
tion of 2-coumariylidene malononitrile with active methylene containing com-
pounds.
4. β−Siloxy acrylonitrile were reacted with chalcones to furnish the respective 3-
cyano-4H-pyran derivatives14.
5. Assay M. G. et al.15 have synthesized some cyanopyran derivatives by the
reaction of cyclohexenone with cinnamon nitriles.
6. De Lera Angel R. and co-workers16 synthesized pyran derivatives by thermal
electrolutic ring closure of divinylallenals.













































































The reaction mechanism for the formation of pyran derivatives proceeds through
Micheal addition of active methylene group of malononitrile to the β−carbon atom of
chalcone described as under.
THERAPEUTIC IMPORTANCE
Polysubstituted pyran derivatives are biologically interesting class of com-























M. A. Al-Haiza and co-workers32 prepared some cyanopyran derivatives (I) and
tested their antibacterial and antifungal activities. Samet A. V. 33 et al. aynthesized 2-
amino-5-azolyl-3-cyano-4H-pyrans (II) and evaluated for biological activity. Elassar A.
Z. et al.34 reported that cyanopyran exhibited in vitro antifungal and antibacterial activi-
ties.
Moreover, Shaker R. M.35 have prepared some coumarin ring containing 2-amino-
3-cyanopyran (III) derivatives and studied their antimicrobial activity. Kulkarni Y. D.
and co-workers36 synthesized some pyran derivatives as CNS active agents. A. A.
Hassainien et al.37 prepared 2-amino-3-cyano-7,7-dimethyl-4-substitutedphenyl-5-oxo-


























Furthermore, Krauze, A. et al.38 synthesized 5-(4-pyridyl)derivatives of 2-amino-
4H-pyran (IV) for antimicrobial activity. Fowzia S. Al-Saleh39 and coworkers synthesized
some new cyanopyran derivatives and reported them as antimicrobial agents. Some
pyran derivatives have been pantented for their use as gastric acid secretion inhibi-
tors40, inhibitors of cell proliferation41, antihypertensive42, antitumor43, antagonists44,45 and
antiviral agents46.
Joshi et al47. recently have synthesized some new cyano pyridine (V) derivatives
as anticancer and antimicrobial agents.
Thus with an effort to capitalize the biological potential of the heterocyclic system
and to synthesize interesting compounds having better biological potential, the titled
compounds have been investigated, which have been described as under.

















SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-4-ARYL-6-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLIN-3-YL)-4H-PYRAN-3-CARBONITRILE
Cyanopyran derivatives have been reported to have various pharmacological
activities like antibacterial, antisecreatary, antiviral, antifungal etc. In order to devel-
ope better medicinaly important compounds, it was considered of interest to synthe-
size some cyanopyran derivatives shown as under. Cyanopyran derivatives of Type-
(VII) have been synthesized by the reaction of the chalcones of Type-(I) with
malononitrile in pyridine.
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activitytowards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concen tration of 40 µg/ml. The bio-






















IR SPECTRAL STUDY OF 2-AMINO-4-(4-METHOXY PHENYL)-6-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLIN-3-YL)-4H-PYRAN-3-CARBONITRILE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2923 2975-2950 48
-CH3 C-H str. (sym.) 2854 2880-2860 “
C-H def. (asym.) 1488 1470-1435 “
C-H def. (sym.) 1353 1385-1370 “
Aromatic C-H str. 3093 3080-3030 49
C=C str. 1596 1620-1430 “
C-H i.p. def 1233 1269-1013 “
C-H o.o.p. def.  825     833-660 “
Ether C-O-C str. 1249 1275-1200 48
Pyran C=C str. 1622 1650-1520 49
Nitrile C=N str. 2202 2240-2120 “
Halide C-Cl str. 729     750-700 48
Amino NH2- str. 3336 3550-3250 49













Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 3.77 3H singlet Ar-OCH3
2. 5.70 1H doublet Ar-Hc (pyran ring)
3. 7.73 2H double duoblet Ar-Ha (p-sub.)
4. 7.76 1H duoblet Ar-Hd
5. 7.56 1H singlet Ar-Hf
6. 7.63 1H doublet Ar-Hg
7. 7.96 1H doublet Ar-Hb (p-sub.)
8. 8.01 2H singlet Ar-He
PMR SPECTRAL STUDIES OF 2-AMINO-4-CHLORO-6-(6-CHLORO-4-OXO-
3,4-DIHYDROCINNOLIN-3-YL)-4H-PYRAN-3-CARBONITRILE


































SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-4-ARYL-6-(6-
CHLORO-4-OXO-3,4-DIHYDROCINNOLIN-3-YL)-4H-PYRAN-3-CARBONITRILE.
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of 2-amino-4-(4-methoxy phenyl)-6-(6-chloro-4-oxo-3,4-dihydro
cinnolin-3-yl)-4H-pyran-3-carbonitrile
A mixture of 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-
one (3.4 gm, 0.01 mol) and malononitrile (1.29g, 0.01 mol) dissolved in pyridine was
refluxed on oil bath for 10 hr. The reaction mixture was cooled and poured onto crushed
ice. The residue was neutralize with 20% HCl, where upon a solid separated out which
was filtered and crystallized from toluene. Yield 53 %, m.p. 220 0C Anal. Calcd. for
C18H12ClN3O3 Requires: C, 62.00; H, 3.72; N, 13.77 % Found: C, 61.97; H, 3.71, N,
13.74 %.
Similarly, other 2-amino-4-aryl-6-(6-chloro-4-oxo-3,4-dihydrocinnolin-3-yl)-4H-
carbonitrile. The physical data are recorded in Table No. 7.
(C) Biological screening of 2-Amino-4-aryl-6-(6-chloro-4-oxo-3,4-dihydro
cinnolin-3-yl)-4H-pyran-3-carbonitrile
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The




























































































































































































































































































































































































































































   
   
   
   
   



















































































































B.mega 15 24 17 21 20 13 15 13 11 18 20 18 20 21
B.substilis 16 12 15 12 13 12 17 11 21 17 24 17 18 24
P.vulgaris 23 14 22 16 14 19 22 17 12 15 21 25 15 25
E.coli 18 15 17 14 11 11 12 15 15 11 22 24 18 25
A.niger 16 17 15 11 13 14 19 24 13 21 24
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Cyclohexenones are derivatives of cyclohexane with carbonyl grooup at posi-
tion -1 and double bond at position -2 (I). There are different types of cyclohexenone
derivatives but the greatest difference in structure and properties is exerted by the
groups attached to carbon atom.
SYNTHETIC ASPECT
Different methods for the preparation of cyclohexenone derivatives have been
described in literature1-14.
(I) A review of the earlier literature by Gerald et al.15 described representative syn-
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(II) Page Philip C. and co-workers16 have been prepared substituted cyclohexenone
derivatives (II).
(III) Eman H. A. et al.17 have been prepared cyclohexenone derivatives (III) from chal-
cone.



































Cyclohexenone have various medicinal applications such as anthelmintic, hy-
poglycemic, nematocidal, antibacterial,  anti fungal, antiviral,  analgesic etc.
Antiarhythmic activity19 of some cyclohexenone derivatives have been investigated.
Cyclohexenone possess cardiovascular, osteoporosis, menpausal symptoms, estro
gen dependent, cancer activities, which was reported by Jacobsen Poul et al.20.
Eddington N. D. et al.21 synthesize ethyl 4-[(substituted phenyl)amino]-6-methyl-
2-oxocyclohex-3-ene-1-carboxylates (I) and screened their anticonvulsant activity.
Cragoe, Edward J. et al.22 also prepared 2,3-dihydro-5-(3-oxo-2-cyclohexen-1-yl)-2-
benzofurancarboxylic acids (II) and their salts which are used in the treatment of brain
injury.
Cyclohexenone and its derivatives have been prepared and reported as broad
spectrum of physiological properties viz., antibiotics23,24, bactericidal25, herbicidal26,
antimicrobial27, anticonvulsant28 etc. Alekseeva L. M. and co-workers29 have synthe-
sized cyclohexenone derivatives which are as useful as neurotropic activity. Toshiyuki
et al.30 have prepared some novel cyclohexenone and screened for allergy inhibitor,





























Recently, antimicrobial activity have been studied by Salama and Atshikh31.
Cyclohexenone possess neutropeptide γ-receptor antagonist activity which was re-
ported by Takehiro and co-workers32. Broughton Howard33 have demonstrated
cyclohexenone as GABA α5 receptor ligands for enhancing coagulating properties.
Cyclohexenone possess inhibitory activity against the growth of lettuce seeding found
by Kimura and co-workers34.
The presence of pesticidal activity among cyclohexenone derivatives is well
documented. The compound 2-{(E,Z)-1-[(2R,S)-2-(4-chlorophenoxy)propoxy
imino]butyl}-3-hydroxy-5-thian-3-yl)cyclohex-2-en)-one (III) has been marketed under
the name of ‘Profoxydim’ as an herbicides.
These valid observation led us to synthesize new cyclohexenone derivatives
bearing cinnoline nucleus in search of agent having better therapeutic potential which
have been described as under.
SECTION-I: Synthesis and biological screening  of  Ethyl-6-aryl-4 -(6-
chloro-4-oxo-3,4-dihydrocinnoline-3-yl)-2-oxocyclohex-3-
ene-1-carboxylate




Indazole or benzopyrazoles a heterocyclic ring system in which a benzene ring
is fused to two carbon atoms of a pyrazole ring , is capable of existing in three tauto-
meric forms (I, II, III)35. Although the chemistry of indazoles has been extensively stud-
ied, they have not been found in natural products and are at the present time of little
commercial use. It was first described by Buchner in 1869.
SYNTHETIC ASPECT
Several methods36-41 are available for the preparation of indazoles. Some of
these are as under,
(I) The most frequently used route for synthesis of indazole ring system consists of
the diazotization of substituted anilines, e.g. o-toludine leds to the parent inda-
zoles42.
(II) Okhim L. Yu et al.43 synthesized some indazole derivatives by heating benzylidene




















Studies on Heterocyclic. . .
Studies on Indazole...
137
(III) Shri Niwas and co-workers44 have synthesized few indazole derivatives from
cyclohexenone intermediates.
(IV) Indazoles may conveniently be prepared by heating o-nitroso-N-benzoltoluidine
in benzene solution.
(V) Another synthesis is that due to Ainsworth (1957).
(VI) Qui-Guo Fu et al.45 have reported that in presence of PPA 2,6-dialkoxyl or hy-
droxyl acetophenone hydrazones were cyclized to indazoles.
(VII) Recently, a facile synthesis of substituted indazoles from 2-acyl aryl mesylates


























































The indazoles has attracted considerable attention in the last 25 years, because
of several commercially useful drugs contain pyrazole ring system. For example Anti-
pyrine (I) has potent antipyretic activity. Similarly Butazolidine (II) has proved a pow-
erful antiinflammatory drug used for rheumatic patients. Pyrazofurin (III) shows activ-


















Et(I) (II) (III) (IV)














Ooe Takanon et al.61 synthesized some indazole derivatives which showed ac-
tivity for enhansing macrophage phagocytosis, improving immunity and antitumor ac-
tivity. Yamaguchi Masahisa et al.62 prepared some indazole derivatives as novel
antiasthametic agents with dual activities of thromboxane A2 synthetase inhibitors and
bronchodialtion. The remarkable cytotoxic activity of indazole derivatives have been
reported by Aran Vincente J et al.63.
Moreover, Effland Richard Charles et al.64 synthesized 3-(pyridylamino)-
indazoles(V) and reported their use as antidepressants and anxiolytics. Some sulfo-
nyl indazoles (VI) synthesized by Duzinska Usarewicz et al65 have been found to pos-
sess antiinflammtory activity. Butera John et al.66 prepared some indazole derivatives
which are useful as potassium channel activators.
Recently, Nishino, Shigehide et al.67 prepared 3-carboxy-5-(1-carboxy ethyl)
indazole (VII) which was used as intermediate for the preparation pesticides. Stack,
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Furthermore, Fukunaga K et al.69 reported that DY-97603, 3-[2-[4-(3-chloro-2-
methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole
dihydrochloride, a novel calmodulin antagonist, possesses neuroprotective activity. Mosti
L. et al.70 synthesize novel N-substituted 1-amino-3-[1-methyl(phenyl)-1H-indazol-4-
yloxy]-propan-2-ols as potential antiarrhythamic, local anaesthetic and analgesic agents.
Lee F Y and co-workers71 synthesized 1-benzyl-3-(5’hydroxymethyl-2’-furyl)indazole ana-
logues as novel antiplatelet agents. Pinna G A et al.72 have synthesized bis
benzo[g]indazol-3-carboxamides and related dimers and checked their antiproliferative
activity.
In light of wide varieties of biological activities exhibited by indazoles, it appeared
of interest to synthesize indazole derivatives, in order to achieving compounds having
better therapeutic activity described as under.
SECTION-II: Synthesis and biological screening of 6-Chloro-3-(4-aryl-3-
oxo-3,3a,4,5-tetrahydro-2H-indazol-6-yl)-cinnolin-4(3H)-one




SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-6-ARYL-4-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLINE-3-YL)-2-OXOCYCLOHEX-3-ENE-1-CARBOXY-
LATE
Cyclohexenone derivatives have considerable attention in view of their poten-
tial pharmacological properties such as antimicrobial, anticonvulsant anticancer, etc.
Led by these considerations, the preparation of cyclohexenone derivatives of Type-
(VIII) has been undertaken. The synthesis was carried out by the condensation of 6-
chloro-3-[(2E)-3-arylprop-2-enoyl]connolin-4(3H)-ones of Type-(I)with ethyl
acetoactate shown as under.
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectros-
copy and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-

















Type-(VIII) R = Aryl
Studies on Heterocyclic. . .
Studies on Indazole...
142
IR SPECTRAL STUDY OF ETHYL-6-(4-CHLORO PHENYL)-6-(6-CHLORO-4-
OXO-3.4-DIHYDROCINNOLIN-3-YL)-2-OXO-CYCLOHEXE-3-ENE-1-CAR-
BOXYLATE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2967 2975-2950 73
-CH3 C-H str. (sym.) 2884 2880-2860 “
C-H def. (asym.) 1479 1470-1435 “
C-H def. (sym.) 1362 1385-1370 “
Aromatic C-H str. 3032 3080-3030 74
C=C str. 1567 1620-1430 “
C-H i.p. def 1247 1269-1013 “
C-H o.o.p. def.  833   833-660 “
Ether C-O-C str. 1209 1275-1200 73
Carbonyl C=O 1676 1690-1665 “
Ester C(=O)OCH2CH3 1749 1750-1717 74
Halide C-Cl str. 765 750-700 73










Studies on Heterocyclic. . .
Studies on Indazole...
143
Signal Signal position Relative No. Multiplicity Inference
No. (δ  ppm) of  Proton
1. 1.08 3H triplet -CH2-CH3
2. 2.94 1H double doublet -CHc
3. 3.05 1H double doublet -CHd
4. 3.77 1H multiplate -CHe
5. 3.80 1H singlet -CHg
6. 3.84 1H singlet Ar-OCH3
7. 4.09 2H quateret -CH2-CH3
8. 6.52 1H doublet -CHf
9. 6.92 2H doublet Ar-Ha (p-sub.)
10. 7.20-7.40 4H multiplet Ar-H
11. 7.52 2H doublet Ar-Hb (p-sub.)
PMR SPECTRAL STUDIES OF ETHYL-6-(4-METHOXY PHENYL)-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLINE-3-YL)-2-OXO-CYCLOHEX-3-ENE-1-CARBOXY-
LATE







































SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-6-ARYL-4-(6-CHLORO-
4-OXO-3,4-DIHYDROCINNOLIN-3-YL)-2-OXO-CYCLOHEX-3-ENE-1-CARBOXY-
LATE
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C).
(B) Synthesis of Ethyl-6-(4-methoxyphenyl)-4-(6-chloro-4-oxo-3,4-dihydro
cinnolin-3-yl)-2-oxo-cyclohex-3-ene-1-carboxylate.
To a solution of 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-
4(3H)-one (3.4 gm, 0.01 mol) in dioxane (30 ml), sodium ethoxide (0.15 mol) and ethyl
acetoacetate (2.60 gm, 0.02 mol) was added and the reaction mixture was refluxed
on oil bath for 12 hrs. The reaction mixture was cooled and poured over crushed ice.
The product was isolated and crystallized from toluene. Yield 58 %, m.p. 206 0C Anal.
Calcd. for C25H23ClN2O6 Requires: C, 63.65; H, 4.67; N, 6.19 % Found: C, 63.63;
H, 4.64, N, 6.17 %.
Similarly, other ethyl-6-aryl-4-(6-chloro-4-oxo-3,4-dihydrocinnolin-3-yl)-2-oxo-
cyclohex-3-ene-1-carboxylate. The physical data are recorded in Table No. 8.
(C) Biological screening of Ethyl-6-aryl-4-(6-chloro-4-oxo-3,4-dihydro
cinnolin-3-yl)-2-oxo-cyclohex-3-ene-1-carboxylate.
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The
zones of inhibition of test solution are reported in Graphical Chart No. 8.

































































































































































































































































































































































































































































   
   
   






























































































































































































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(4-ARYL-3-OXO-
3,3a,4,5-TETRAHYDRO-2H-INDAZOL-6-YL)-CINNOLIN-4(3H)-ONE
Various derivatives of indazole exhibit interesting biological properties like
anticancer, antiinflammatory, anticonvulsant, antipyretic etc. With a view to prepare
more potential drug value compounds we have carried out the synthesis of Indazole
derivatives of Type-(IX) have been prepared by the condensation of cyclohexenone deriva-
tives of Type-(VII) with hydrazine hydrate. derivatives, which have been briefed as under.
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectros-
copy and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-
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IR SPECTRAL STUDY OF 6-CHLORO-3-(4-ARYL-3-OXO-3,3a,4 ,5-
TETRAHYDRO-2H-INDAZOL-6-YL)-CINNOLIN-4(3H)-ONE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2922 2975-2950 73
-CH3 C-H str. (sym.) 2852 2880-2860 “
C-H def. (asym.) 1460 1470-1435 “
C-H def. (sym.) 1350 1385-1370 “
Aromatic C-H str. 3033 3080-3030 74
C=C str. 1558 1620-1430 “
C-H i.p. def 1174 1269-1013 “
C-H o.o.p. def.  825   833-660 “
Amide NHC(=O)- str. 1664 1680-1636 73
Indazole C=N 1598 1660-1480 74
Ether C-O-C str. 1249 1275-1200 73
Halide C-Cl str. 750 750-700 “
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       Internal reference: TMS; Solvent: CDCl3; Instrument: BRUKER spectrometer(300 MHz)
Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of  Proton
1. 3.24 1H double doublet -CHc
2. 3.42 1H double doublet -CHd
3. 3.80 1H multiplate -CHe
4. 3.90 3H singlet Ar-OCH3
5. 4.04 1H doublet Ar-Hf
6. 6.97 2H doublet Ar-Ha(p-sub.)
7. 7.1-7.5 4H multiplet Ar-H
8. 7.94 2H doublet Ar-Hb (p-sub.)
































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(4-ARYL-3-OXO-
3,3a,4,5-TETRAHYDRO-2H-INDAZOL-6-YL)-CINNOLIN-4(3H)-ONE
(A)          Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-oyl]cinnolin-4(3H)-one
             See Part-I, Section-I (A)
(B)        Synthesis of Ethyl-6-aryl-4-(6-chloro-4-oxo-3,4-dyhydro cinnolin-3-yl)-2-
             oxo-cyclohex-3-ene-1-carboxylate
             See Part-VI, Section-I (B)
(C)        Synthesis of 6-Chloro-3-[4-(4-methoxy phenyl)-3-oxo-3,3a,4,5-tetrahy
             dro-2H-indazol-6-yl]-cinnolin-4(3H)-one
               A mixture of Ethyl-6-(4-methoxyphenyl)-4-(6-chloro-4-oxo-3,4-dyhydro cinnolin-
3-yl)-2-oxo-cyclohex-3-ene-1-carboxylate (gm, 0.01 mol) and hydrazine hydrate (0.05
gm, 0.01 mol) were refluxed in ethanol (50 ml) containing 1-3 ml gl. acetic acid, on a
water bath for 5 hr. The residue obtains after cooling was filtered and crystallized from
methanol. Yield 43%, m. p. 1590C; Anal. Calcd. for C22H17ClN4O3: C, 62.79; H, 4.07;
N, 13.31%, found: C, 62.77; H, 4.04; N, 13.30%.
             Similarly other 6-chloro-3-(4-aryl-3-oxo-3,3a,4,5-tetrahydro- 2H-indazol-6-yl)
-cinnolin-4(3H)-ones were prepared. The physical data are recorded in Table No. 9.
(D)        Boiological evaluation of 6-Chloro-3-(4-aryl-3-oxo-3,3a,4,5-tetrahydro-
             2H-indazol-6-yl) -cinnolin-4(3H)-ones
             Antimicrobial testing were carried out as described in Part-I, Section-I (D).
The zones of inhibition of test solutions are recorded in Graphical Chart No. 9.

























































































































































































































































































































































































































































































   
   
   
   
   


















































































































B.mega 18 17 19 17 21 20 17 18 19 19 19 20 18 20 21
B.substilis 15 14 16 16 13 16 14 13 15 15 15 24 17 18 24
P.vulgaris 12 20 14 18 21 14 22 16 10 14 11 21 25 15 25
E.coli 16 21 17 15 17 16 16 16 15 14 16 22 24 18 25
A.niger 18 18 17 16 19 19 18 19 18 20 17 24
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Large number of derivatives of benzothiazepines have been found to exhibit a
wide variety of biological  act iv i ty.  Many pharmacological  composit ions of
benzothiazepines have been patented1-4 and some of the popularly used drugs are
Thiazesim, Diltiazem5 and Clentienzem6 etc.
SYNTHETIC ASPECT
On account of their main fold implications, a plethora of 1,5-benzothiazepines
have been synthesized and numerous strategies worked upon for the purpose. Reac-
tions of 2-amino thiophenol with chalcones seems to be the most explored route for
the synthesis of benzothiazepines.
Yang et al.7 have reported cyclocondensation of RC6H4CH:CHCOMe with 2-
amino thiophenol to accomplish dihydrobenzothiazepines(I) which were reduced by














2-Amino thiophenol can be reacted with 1,3-biscarbon electrophiles to give
variouss types of 1,5-benzothiazepine. Thus the benzo analogus of (III) and (IV), e.g.,
(V), are prepared by parallel routes, reaction with 1,3-diphenyl propynone gives (VI),
reaction with β-ketoesters gives products of type (VII), reaction with diketene gives
(VIII), and the reaction with methyl-3-arylglycidates gaves (IX) which could not be dehy-
drated.
As with 1,4-oxazepines the Schmidt reaction of cyclic ketones and the Beckmann
rearrangement of their oximes can be applied to the synthesis of monocyclic 1,4-
thiazepines, 1,4- and 1,5-benzothiazepines and their 1-oxides and 1,1-dioxides8.
Thioxanthen-9-one, 10,10-dixides, on treatment with sodamide in liquid ammo-
nia, undergo a novel ring expansion to give dibenzo[b,f][1,4]-thazepine-11-one-5,5-
dioxides9. The thiazolium salt (X) undergoes base-induced ring expansion to give (XI)10,
























































Moreover, A. K. Sharma and co-workers11 have find out new method for the prepa-
ration of new 1,5-benzothiazepine, they prepared ( + ) cis-2-(4-methoxyphenyl)-3-hy-
droxy/methoxy-2,3-dihydro-1,5-benzothiazepine-4[5H/5-chloroacetyl /5-(4’-
methylpiperazino-1’)-acetyl]-ones by the condensation of 2-amino benzene thiols with
methyl ( + ) trans-3-(4-methoxy phenyl)glycidate in xylene.
Recently, M.Wichers and K. Gorlitzer12 synthesize the 6,12-dihydro benzofuro[2,3-
c][1,5]-benzothiazepines by heating (Z)-2-benzylidene-3(2H)-benzofuranonesand (Z)-



































Mechanism of reaction of chalcones with 2-aminothiophenol can be visualized
as formulated below.
The reactions of 2-amino benzene thiols with the chalcone is initially a
nucleophilic addition13 to give a type of Michael adduct which is formed by the attack
of the lone pair of sulphydryl electrons over the β-carbon of chalcone to give a
ketoamine. The latter tautomerizes to the enolic form which on dehydrative cyclization
results in the formation of the final product.
THERAPEUTIC INTEREST
The importance of the 1,5-benzothiazepine nucleus has large number of patents
as chemotherapeutic agents, available on it. A number of biological activities have










































1,5-Benzothiazepine class of compounds have given calcium channel blockers
of proven utility such as Diltiazem and those in which fused benzene ring is substi-
tuted at various positions have been found to have enhanced pharmacological prop-
erties.
Moreover, A. K. Sharma25 and other co-workers synthesize new derivatives of
1,5-benzothiazepine (I) as analogus of anticancer drugs. Micheli F., et al.26 led to com-
binatorial approach to [1,5]-benzothiazpine derivatives as potential antibacterial
agents. Shetgiri N. P. et al.27 also derived some new derivatives of benzothiazepine
as antimicrobial activities.
2,5-Disubstituted-3,4-dihydro-2H-benzo[b][1,4]thiazepine featured as potent and
selective V(2) arginine vasopressin receptor antagonists by Urbanski M. J. and et
al.28. Sucheta K. and et al.29 synthesize some new 1,5-benzothiazepines containing




et al.30 check the effects of a novel, potent benzothiazepine as Ca2+channel antago-
nist, DTZ-323 on guinea-pig ventricular myocytes.
Furthermore, Dandia Anshu and et al.31 prepared 8-substituted-2,5-dihydro-1,5-
benzothiazepine-2-spiro-3’-3H-indol-2’(1H)-ones (III) by microwave irradiation and
check their antifungal and antitubercular activities. Meiji, Seika32 reported 1,5-
benzothiazepine as pesticides. Press, Jeffery B. et al.33 prepared 2-phenyl-3,4-dihydro-
2H- and 3,4,5,6-tetrahydro-2H-1,5-benzothiazepine and investigated the prepared
derivatives as centrl nervous systems activity.
Sanwa, Kagaku Kenkyusho34 prepared 1-phenyl-2,5-benzothiazepine derivatives





























benzothiazepine derivatives (IV) which was useful as vasodilators, antithrombotics
and calmodil in inhibitors. Slade, Joel and co-workers36 synthesize hetero-
benzothiazepine derivatives which at 10mg/kg orally in rat lowered blood pressure by
∼35mm Hg.
Some benzothiazepine derivatives are used as a drugs  such as (2R,3R)-5-[2-
(d imethy lamino)ethy l ] -2(4-methoxypheny l ) -4-oxo-2,3 ,4 ,5- te t rahydro-1,5-








































With this in mind, some new 1,5-benzothiazepine derivatives have been synthe-
sized in search of better therapeutic agents, by a convenient single pot method, which
is described as under.






SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(2-ARYL-2,3-
DIHYDRO-1,5-BENZOTHIAZEPINE-4-YL)CINNOLIN-4(3H)-ONES.
Various types of benzothiazepine derivatives shows wide range of biological
activity such as anticancer, antifungal, antimicrobial, antitubercular, antidiabetic etc.
With a view to get better therapeutic agents, we have synthesized different types of
benzothizepine derivatives of Type-(X) have been prepared by condensation of chal-
cones of Type-(I) and 2-amino thiophenol in presence of piperidine, which have been
described as under.
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-



















IR SPECTRAL STUDY OF 6-CHLORO-3-(2-(4-METHOXY PHEBYL)-2,3-
DIHYDRO-1,5-BENZOTHIAZEPINE-4-YL)CINNOLIN-4(3H)-ONE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2927 2975-2950 37
-CH3 C-H str. (sym.) 2854 2880-2860 “
C-H def. (asym.) 1460 1470-1435 “
C-H def. (sym.) 1352 1385-1370 “
Aromatic C-H str. 3033 3080-3030 38
C=C str. 1548 1620-1430 “
C-H i.p. def 1238 1269-1013 “
C-H o.o.p. def.  869   833-660 “
Ether C-O-C str. 1238 1275-1200 37
Carbonyl C=O 1661 1690-1665 “
Halide C-Cl str. 740 750-700 “
















































Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 3.77 3H singlet Ar-OCH3
2. 5.78 1H multiplate Ar-CH2
3. 6.81 3H multiplate Ar-H (cinnoline ring)
4. 7.25 1H singlet Ar-H
5. 7.73 2H doublet Ar-Ha(p-sub.)
6. 7.87 1H doublet Ar-H
7. 7.96 2H double Ar-Hb (p-sub.)
8. 8.41 1H singlet Ar-NH






























SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(2-ARYL-2,3-
DIHYDRO-1,5-BENZOTHIAZEPINE-4-YL)CINNOLIN-4(3H)-ONES.
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of  6-Chloro-3- [2- (4-mehtoxyphenyl ) -2 ,3-dihydro-1,5-
benzothiazepin-4-yl]cinnolin-4(3H)-one.
A mixture of 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-
one (3.4 gm, 0.01 mol), 2-amino thiophenol (0.68 gm, 0.01 mol) in ethanol containing
gl. acetic acid was refluxed on oil bath for 4 hr. The reaction mixture was cooled and
poured onto crushed ice. The product was isolated and crystallized from toluene. Yield
55 %, m.p. 117 0C. Anal. Calcd. for C24H18ClN3O2SRequires: C, 64.35; H, 3.42; N,
9.38 % found: C, 64.10; H, 3.40, N, 9.36 %.
Similarly, other 6-chloro-3-(2-aryl-2,3-dihydro-1,5-benzothiazepin-4-yl)cinnolin-
4(3H)-one. The physical data are recorded in Table No. 10.
(C) Biological  screening of  6-Chloro-3- [2-aryl -2 ,3-dihydro-1,5-
benzothiazepin-4-yl]cinnolin-4(3H)-one.
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The




































































































































































































































































































































































































































































   
   
   
   
   


























































































B.mega 20 21 14 21 14 20 15 14 15 16 20 18 20 21
B.substilis 14 14 17 15 15 17 13 20 14 15 24 17 18 24
P.vulgaris 24 11 15 17 22 14 22 12 13 11 21 25 15 25
E.coli 14 12 22 15 15 18 15 14 24 13 22 24 18 25
A.niger 19 14 13 14 19 21 14 14 11 20 24
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Thiazole may be considered to be derived from benzene by replacing a CH group
with a nitrogen atom and a CH=CH group, at position 3 and 4 of the corresponding
pyridine with a sulfur atom. The chemistry of thiazole therefore shows similarities to
those of pyridine and thiophene. Hence the thiazole ring (I) was first described by
Hantzch and Weber1 in 1987 as "the pyridine of the thiophene series".
The groups of compound containing the thiazole moiety are a prominent struc-
tural feature in a variety of natural products, like Vitamin B, and penicillin as well as in
other compounds of medicinal interest and have attracted attention for their biological
activities. They constitute the skeleton of antibiotics such as Althomyccin2 and Micro-
coccin3 as do many metabolites of living organisms. Even first synthetic drug bearing
thiazole moiety i. e., "Sulphathiazole" derived from 2-amino thiazole has many appli-


























The thiazole ring was first described in 1987 by Hantzch, the cyclisation of α-
halo carbonyl compounds by a great variety of reactants bearing the N-C-S fragment
of the ring is still the most widely used method of synthesis of thiazoles.
1. α-Bromo alkynes also give 2-mercaptothiazoles by condensation with ammo-
nium dithiocarbamate in alcohol solution.
2. 1,3-Oxathiolylium salts condense with cyanamide in the presence of sodium
ethoxide to give an open chain intermediate, which cyclizes to substituted 4-
aminothiazoles4.






































4. Isothiocyanate condense with α-aminonitriles affording 2-substituted-5-amino
thiazoles through an acyclic intermediates. In some cases the 2,5-disubstituted amino
thiazoles was isolated as a by product.
REACTION MECHANISM
The mechanism of the Hantzch synthesis has been established and is shown in
scheme. Substitution of the halogen atom of the α-haloketone by the sulfur atom of the
thioamide occurs first to give an open chain a-thioketone, which under transprotonation
proceeds to give a 4-hydroxy- ∆2-thiazoline in aprotic solvents or a thiazole by acid
catalyzed dehydration of the intermediate thiazolines in protic solvents.
THERAPEUTIC IMPORTANCE
2-Amino thiazole derivatives exhibit a variety of biological activities. One of the
first synthetic drug bearing thiazole moiety as “Sulphatiazole (I)”, a simple
sulphanomide antibiotic derived from 2-amino thiazole. It has bacteriostatic effects













































promizole, which are used in intestinal infections and for the treatment of leprosy re-
spectively.
Aminitrozole i.e. 2-acetamido-5-nitrothiazole has been used for intestinal
amobiasis in rats and dogs at well-tolerated doses6. From this conclusion it led to the
synthesis of Niridazole7 [1-(5-nitro-2-thiazolyl)-2-imidazolidinone] (II), which showed
the in vitro activity against E.histolytica at a concentration of 10 µg/ml. Many other
activities were also exhibited such as antiamoebic and antischistosomal8-10 by D. B.
Capps and M. Avramoff.
Lombardino and wiseman have prepared sudoxucam (III), and reproted their
potent antiinflammatory activity11 at a concentration of 0.3 mg/kg doses.
2-Amino-4-aryl-5-thiazole carboxylic derivatives (IV) showed antiinflammatory,
antipyretic, analgesic and antitumor activity12 in mice at 560 mg/kg intraperitoneal (I.






























N-Phenyl-N’-(2-thiazolyl)urea have displayed potential antiparkinson, anthelmintic and
trichomodial activities13,14. Screening data of 4-(isoxazolyl)thiazol-2-oxamic acid de-
rivatives revealed their antiarthritics, antiallergic and antianaphylactic activity15,16. P.
N. Bhargava17 have synthesized 2,6-diaryl-3-ethoxy carbonyl-4-piperidino acetyl-2’-
amino-4’-phenyl thiazole (VI) as local anesthetic .
Some new tetrahydropyrimidinyl substituted 2-amino thiazole derivatives showed
in vitro activity against Trichopyton mentagrophyts and Candida albicans18 at a con-
centration of 2-4 µg/ml. Hypoglycemic activity of 2-amino thiazole have been studied
by Alfred et al.19. Kwang and co-workers20 have prepared 2’-(2-amino ethyl)-2,4’-
bithiazole-4-carboxylic acid which possess antitumor and antibiotic activity. Ahluwalia
et al.21 synthesized amino thiazole derivatives of type (VII) having antimicrobial activ-
ity against S.aureus and E.coli at 10-25 µg/ml.
Saldabols and Medhe22 have reported substituted amino thiazole derivatives




















Moreover compounds bearing thiazole moiety are reported to possess antiin-
flammatory23,24, anticonvulsant25, nematocide26, antitubercular27,28, antiviral29, insecti-
cidal30, herbicidal31,32, pesticidal33, antifungal34,35 and antibacterial36,37 activities.
2-Substituted amino thiazole derivatives were prepared as antipsychotics agent
by Rao38, and N. Atsuo39,40. S. Masaru41 and co workers have synthesized 2-amino-
4,5-diphenyl derivatives and useful as inhibitors of blood platelet aggregation.
Very recently antiinflammatory activity42 of substituted 2-amino-4-carboxy-5-thia-
zole acetic acid by Patil and co-workers have been described. Joshi et al.43 have
prepared 3’-(4-aryl-2-thiazolyl)-6’-aryl-imidazo(2,1-b)thiazole as apossible antibacte-
rial agent. In vitro activity of some new and known members of cephalosporin antibiot-
ics with amino thiazole moety are described by M. Valencie44. Thienyl thiazole deriva-
tives as tested against Helicobacter phylori 800445 has a MIC of 0.2 µg/ml.     Thus the
important role displayed by thiazole moiety for various physiological activities
prompted us to synthesized some thiazole derivatives bearing 6-chloro cinnolin-4(3H)-
one moiety. This study is described in the following part.










SYNTHESIS AND BIOLOGICAL SCREENING OF (1E)-ARYL-[4-(6-CHLORO-4-
OXO-3,4-DIHYDROCINNOLIN-3-YL)-1,3-THIAZOL-2-YL]HYDRAZONE.
Various types of thiazole derivatives shows wide range of biological activity such
as anticancer, antifungal, antimicrobial, antitubercular, antidiabetic etc. With a view to
get better therapeutic agents, we have synthesized different types of thiazole deriva-
tives which have been described as under. Thiazole derivatives of Type-(XI) have been
prepared by condensation of bromo acetyl cinnoline with different types of
thiosemicarbazones, which was prepared by the condensation of aryl aldehyde and
thiosemicarbazide.
The structure elucidation of synthesized compounds have been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-




























Type-(XI)   R = Aryl
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IR SPECTRAL STUDY OF (1E)-ARYL-[4- (6-CHLORO-4-OXO-3,4-
DIHYDROCINNOLIN-3-YL)-1,3-THIAZOL-2-YL]HYDRAZONE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2923 2975-2950 46
-CH3 C-H str. (sym.) 2854 2880-2860 “
C-H def. (asym.) 1488 1470-1435 “
C-H def. (sym.) 1384 1385-1370 “
Aromatic C-H str. 3033 3080-3030 47
C=C str. 1527 1620-1430 “
C-H i.p. def 1238 1269-1013 “
C-H o.o.p. def.   825   833-660 “
Amine NH- str. 3321 3300-3450 “
Ether C-O-C str. 1153 1275-1200 46
Halide C-Cl str.   740 750-700 47































Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 3.87 3H singlet Ar-OCH3
2. 6.98 2H doublet Ar-Ha (p-sub.)
3. 7.31 1H double duoblet Ar-Hd
4. 7.36 1H double duoblet Ar-Hf
5. 7.56 1H doublet Ar-He
6. 7.63 1H doublet Ar-Hg
7. 7.75 1H singlet Ar-Hc (pyridine)
8. 8.03 2H doublet Ar-Hb (p-sub.)
PMR SPECTRAL STUDIES OF 2-AMINO-4-ARYL-6-(6-CHLORO-4-OXO-3,4-
DIHYDROCINNOLIN-3-YL)NICOTINONITRILE































(A) Synthesis of 3-Bromoacetyl-6-chloro cinnolin-4(3H)-one.
Dissolve 3-acetyl-6-chlorocinnolin-4(3H)-one (2.22 gm, 0.01 mol) in 50 ml of
dioxane. To this solution, 1.60 gm (0.01 mol) of bromine in dioxane, was added dropwise
with continuous stirring. The contents were heated at 50 0C for one hr. After cooling the
reaction mixture was poured into the ice cold water. The solid so separated was fil-
tered, washed with cold water, dried and crystallized from ethanol. Yield 65 % m. p.
148 0C.
(B) Synthesis of 4-Methoxybenzaldehyde thiosemicarbazone.
To a solution of thiosemicarbazide (0.9 gm, 0.01 mol) in ethanol (40 ml), 4-methoxy
benzaldehyde (1.36 gm, 0.01 mol) and sodium acetate (0.4 gm) was added and relfuxed
it on water bath for 3-4 hr. The solid mass separated after cooling was filtered, washed
with water, dried and recrystallized from ethanol. Yield 72 % m. p. 128 0C.
(C) Synthesis of  4-Methoxy benzaldehyde [4- (6-chloro-4-oxo-3,4-
dihydrocinnolin-3-yl)-1,3-thiazol-2-yl]-hydrazone.
A mixture of 3-bromoacetyl-6-chlorocinnolin-4(3H)-one (3.01 gm, 0.01mol) and
4-methoxybenzaldehyde thiosemicarbazone (2.09 gm, 0.01 mol) in 50 ml ethanol, was
refluxed on a water bath for about 5 hr. The volume of the reaction mixture was then
reduced to one fourth, after which it was cooled and added ammonia solution with
stirring. The solid so obtained was foltered, washed with water and crystallized from
aqueous ethanol. Yield 55 % m.p. 140 0C. Anal. Calcd. for C19H14ClN5O2S Requires:
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C, 55.41; H, 3.43; N, 17.00 % Found: C, 55.40; H, 3.40, N, 16.98 %.
Similarly, other (1E)-aryl [4-(6-chloro-4-oxo-3,4-dihydrocinnolin-3-yl)-1,3-thiazol-2-yl]-
hydrazone. The physical data are recorded in Table No. 11.
(D) Biological screening of (1E)-aryl [4-(6-chloro-4-oxo-3,4-dihydrocinnolin-3-yl)-
1,3-thiazol-2-yl]-hydrazone.
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The

























































































































































































































































































































































































































































































































   
   
   
   

















































































































B.mega 20 21 14 21 14 20 11 12 15 23 14 20 18 20 21
B.substilis 14 14 17 15 15 17 11 20 14 14 15 24 17 18 24
P.vulgaris 24 11 15 17 22 14 22 13 14 13 14 21 25 15 25
E.coli 14 12 22 15 15 18 15 14 11 15 12 22 24 18 25
A.niger 19 14 13 14 19 21 14 15 18 11 21 24
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In recent years much interest has been focused on the study of the pyrimidine
ring system because of its potential pharmacological activities. Forstly pyrimidine was
isolated by Garbial and Colman in 1899. Pyrimidine ring (I) system consists of two
nitrogen atoms in a sis member heterocyclic ring at 1,3-position.
Purines, uric acid, alkoxan, barbituric acid and a mixture of antimalarial and
antibacteial also contain the pyrimidine ring. The chemistry of pyrimidine has been
widely studied by several co-workers.
SYNTHETIC ASPECT
A very important general method for preparing pyrimidines is the condensation
between a three carbon compounds of the type YCH2Z, where Y and Z = COR, CO2R,
CN, and compounds having the amidine structure R(C=NH)NH2, where R = R (an
amidine), OH (urea), SH or SR (thiourea or its s-derivative), NH2 (guanidine); the con-
densation is carried out in te presence of sodium hysroxide or sodium ethoxide. This






acetoacetate to form 4-hydroxy-2,6-dimethylpyrimidine.
There are many other methods of pyrimidine ring synthesis which are of more
limited scope. The reaction of 1,3-dicarbonyl compound or an equivalent reagent with
formamide provides a route of several pyrimidine which are unsubstituted at the 2-
position.
Pyrimidines can also be prepared by cycloaddition reaction of 1,3,5-triazines,
which act as electron deficient dienes.


























































































The reaction mechanism for the formation of pyrimidine derivatives described
as under.
THERAPEUTIC IMPORTANCE
It is revealed from the literature survey that pyrimidine derivatives have been











Moreover, Chaudhari Bipinchandra and et al.11 prepared N6-(2-aminopyrimidin-
4-yl)-quinoline-4,6-diamine (I) as N-type calsium channel antagonists for the treatment




















antimicrobial activity. Kovalenko A. L.13 synthesized and reported antifungal activity of
pyrimidine derivatives. Shiv P. Singh and co-workers14 synthesized 4-(4-pyrazolyl)-2-
aminopyrimidines(H) and tested them for their antimicrobial activity.
Patil, L. R. et al.15 synthesize some new pyrimidines bearing paracetamol and
imidazolyl moieties. B. J. Ghiya et al.16 synthesized some mercapto pyrimidine de-
rivatives (II) and screened for their anticancer, antitubercular and anti HIV activities.
Kaplina N. V. and co-workers17 exibited herpes inhibiting activity of some mercapto
pyrimidine derivatives.
The pyrimidines uracil (IIIa), thyamine (IIIb) and cytosine (IV) occur very widely
in nature since they are components of nucleic acids, in the form of N-substituted sugar
derivatives. Several analogues have been used as compounds that interfere with the
synthesis and functioning of nulic acids: example are fluorouracil (IIIc), and the anti-
AIDS drug Zidovudine (AZT) (V). Some diaminopyrimidines , including pyrimethamine
(VI) and trimethoprim (VII), are antimalarial agents; trimethoprim is also an effective
antibacterial agent when used in combination with a sulphonamide. Minoxidil (VIII) is
a vasodilator which has been used in the treatment of hypertension. Vitamine B1(IX)
is also a pyrimidine.
S. S. Sangapure and S. M. Mulagi18 have tested the antimicrobial activity of
benzofuro[3,2-d]pyrimidine derivatives (X). El Sayed19  and A. M. Badaway20 have syn-




anticancer and antineoplastic activity. H. Y. Moustafa21 have prepared some pyrimi-
dine derivatives and studied their biological activities.
Some pyrazolo thieno oyrimidine derivatives exhibit antiulcer activity22. Skolova
A. S. and co-workers23 have synthesized 5-amino-6-mercapto pyrimidine possessing
antitumor and cytostatic activity. Hozein Zeinab et al.24 and Khalafallah Ali Kamel25

















IIIa R = H
IIIb R = Me

















































In our study on therapeutically active molecules, we have undertaken synthesis of
pyrimidine derivatives, which have been described in following section.
SECTION-I : Preparation and biological screening of 3-(2-Amino-6-aryl
pyrimidin-4-yl)-6-chlorocinnolin-4(3H)-one






SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(2-AMINO-6-ARYL PYRIMIDIN-
4-YL)-6-CHLOROCINNOLIN-4(3H)-ONE.
Pyrimidines receive an extra ordinary amount of attention by synthetic and me-
dicinal chemists because of their unique role played by this hetero aromatic ring in
biological systems. These results made it interesting to prepare 3-(2-amino-6-aryl
pyrimidin-4-yl)-6-chlorocinnolin-4(3H)-one of type-(XII) by condensing 6-chloro-3-[(2E)-
3-arylprop-2-enoyl]cinnolin-4(3H)-ones of type-(I) with guanidine hydro chloride in pres-
ence of alcoholic potassium hydroxide.
The structure elucidation of synthesized compounds has been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-




















IR SPECTRAL STUDY OF 3- (2-AMINO-6-ARYLPYRIMIDIN-4-YL)-6-
CHLOROCINNOLIN-4(3H)-ONE
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2920 2975-2950 25
-CH3 C-H str. (sym.) 2854 2880-2860 “
C-H def. (asym.) 1452 1470-1435 “
C-H def. (sym.) 1373 1385-1370 “
Aromatic C-H str. 3087 3080-3030 26
C=C str. 1585 1620-1430 “
C-H i.p. def 1247 1269-1013 “
C-H o.o.p. def.  825   833-660 “
Amine NH2- str. 3267, 3355 3450-3300 “
Ether C-O-C str. 1168 1275-1200 25
Carbonyl C=O 1679 1690-1665 26
Halide C-Cl str. 734 750-700 “




















































Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 3.78 3H singlet Ar-OCH3
2. 5.43 1H singlet Ar-CHc
3. 7.25 1H singlet Ar-H (cinnoline ring)
4. 7.30 2H doublet Ar-H (p-sub.)
5. 7.36-7.90 3H multiplate Ar-H
6. 7.96 2H double Ar-H (p-sub.)
7. 8.74 2H singlet Ar-NH2






























SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(2-AMINO-6-ARYLPYRIMIDIN-
4-YL)-6-CHLOROCINNOLIN-4(3H)-ONE
(A) Synthesis of 6-Chloro-3-[(2E)-3-aryl-prop-2-enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of  3- [2-Amino-6-(4-methoxyphenyl)pyr imidin-4-yl ] -6-
chlorocinnolin-4(3H)-one.
A mixtureof 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-
one (3.4 gm, 0.01 mole) and guanidine hydrochloride (1.10g, 0.01 mol) was refluxed
on a water-bath in presence of alcoholic KOH in dioxane for 8 hr. The solvent was
evaporated and the residue was neutralized with 20 % HCl, the separated solid was
filtered out and crystallized from ethanol. Yield 46 %, m.p. 304 0C Anal. Calcd. for
C19H14ClN5O2 Requires: C, 60.09; H, 3.72; N, 18.44 % Found: C, 60.05; H, 3.70, N,
18.42 %.
Similarly, other 3-(2-Amino-6-arylpyrimidin-4-yl)-6-chlorocinnolin-4(3H)-ones.
The physical data are recorded in Table No. 12.
(C) Biological screening of 3-(2-Amino-6-arylpyrimidin-4-yl)-6-chlorocinnolin-
4(3H)-one
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The





























































































































































































































































































































































































































































   
   
   
   
   
































































































B.mega 19 19 14 12 20 18 15 15 17 26 20 18 20 21
B.substilis 13 18 12 15 12 15 13 14 11 12 24 17 18 24
P.vulgaris 24 15 12 17 22 12 20 17 13 12 21 25 15 25
E.coli 12 11 14 21 24 16 15 12 10 13 22 24 18 25
A.niger 15 11 13 18 12 21 17 12 14 18 24
















SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(6-ARYL-2-
MERCAPTO-3,4-DIHYDROPYRIMIDIN-4-YL)CINNOLIN-4(3H)-ONES.
Pyrimidines have been studied extensively because of their ready accessibility,
diverse chemical reactivity and broad spectrum of biological activities. Led by these
considerations the synthesis of pyrimidine derivatives of type-(XIII) has been under-
taken by the cyclocondensation of 6-chloro-3-[(2E)-3-arylprop-2-enoyl]cinnolin-4(3H)-
ones of type-(I) with thiourea in presence of alcoholic KOH.
The structure elucidation of synthesized compounds has been done on the ba-
sis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The bio-














IR SPECTRAL STUDY OF 6-CHLORO-3-(6-ARYL-2-MERCAPTO-3,4-
DIHYDROPYRIMIDIN-4-YL)CINNOLIN-4(3H)-ONES
Type Vibration     Frequency in cm-1 References
mode Observed Reported
Alkane C-H str. (asym.) 2935 2975-2950 25
-CH3 C-H str. (sym.) 2854 2880-2860 “
C-H def. (asym.) 1469 1470-1435 “
Aromatic C-H str. 3033 3080-3030 26
C=C str. 1560 1620-1430 “
C-H i.p. def 1258 1269-1013 “
C-H o.o.p. def.   827   833-660 “
Ether C-O-C str. 1161 1275-1200 25
Halide C-Cl str.   765 750-700 26











































Signal Signal position Relative No. Multiplicity Inference
No. (δ ppm) of Proton
1. 3.87 3H singlet Ar-OCH3
2. 6.61 1H doublet Ar-CHc
3. 7.00 3H multiplate Ar-Ha
4. 7.69 1H singlet Ar-H (cinnoline ring)
5. 7.78 2H doublet Ar-H (p-sub.)
6. 7.97 1H doublet Ar-Hd
7. 7.80 2H doublet Ar-H (p-sub.)
8. 8.41 1H singlet Ar-NH

































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-CHLORO-3-(6-ARYL-2-
MERCAPTO-3,4-DIHYDROPYRIMIDIN-4-YL)CINNOLIN-4(3H)-ONES.
(A) Synthesis of  6-Chloro-3- [ (2E)-3- (4-methoxyphenyl ) -prop-2-
enoyl]cinnolin-4(3H)-one.
See Part-I, Section-I(C)
(B) Synthesis of  6-Chloro-3-[6-(4-methoxy phenyl) -2-mercapto-3,4-
dihydropyrimidin-4-yl)cinnolin-4(3H)-one.
A mixtureof 6-chloro-3-[(2E)-3-(4-methoxyphenyl)-prop-2-enoyl]cinnolin-4(3H)-
one (3.4 gm, 0.01 mole) and thiourea (0.78g, 0.01 mol) was refluxed on a water-bath
in presence of alcoholic KOH in dioxane for 10 hr. The solvent was evaporated and
the residue was neutralized with diluted HCl, the separated solid was filtered out and
crystallized from ethanol. Yield 51 %, m.p. 200 0C Anal. Calcd. for C18H12ClN3O3
Requires: C, 61.11; H, 3.42; N, 11.88 % Found: C, 61.10; H, 3.40, N, 11.84 %.
Similarly, other 6-chloro-3-[6-aryl-2-mercapto-3,4-dihydropyrimidin-4-yl)cinnolin-
4(3H)-ones The physical data are recorded in Table No. 13.
(C) Biological  screening of  6-Chloro-3- [6-aryl -2-mercapto-3,4-
dihydropyrimidin-4-yl)cinnolin-4(3H)-ones.
Antimicrobial testing were carried out as described in Part-I, Section-I(D). The






































































































































































































































































































































































































































































































   
   
   
   










































































































B.mega 14 15 12 14 13 10 18 15 13 17 20 18 20 21
B.substilis 13 12 10 15 19 13 14 16 15 17 24 17 18 24
P.vulgaris 18 12 13 18 19 17 13 15 12 18 21 25 15 25
E.coli 18 14 14 16 13 15 14 17 14 14 22 24 18 25
A.niger 11 15 16 12 14 16 18 12 13 14 24
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Sr. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
 No. Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
1a C6H5- C17H11ClN2O2 310.73 210 0.563 S1 74 9.02 9.02
1b 3-Br-C6H4- C17H10BrClN2O2 389.63 198 0.527 S1 71 7.19 7.15
1c 2-Cl-C6H4- C17H10Cl2N2O2 345.18 220 0.366 S2 72 8.12 8.11
1d 3-Cl-C6H4- C17H10Cl2N2O2 345.18 174 0.542 S2 65 8.12 8.06
1e 4-Cl-C6H4- C17H10Cl2N2O2 345.18 170 0.538 S2 59 8.12 8.08
1f 3,4-(OCH3)2-C6H4- C19H15ClN2O4 370.78 178 0.543 S1 64 7.56 7.54
1g 4-OCH3-C6H4- C18H13ClN2O3 340.76 190 0.465 S2 68 8.22 8.20
1h 4-SCH3-C6H4- C18H13ClN2O2S 356.83 204 0.450 S2 54 7.85 7.83
1i 3-NO2-C6H4- C17H10ClN3O4 355.73 206 0.556 S2 72 11.81 11.80
1j 2-OH-C6H4- C17H11ClN2O3 326.73 212 0.500 S2 75 8.57 8.54
1k 4-OH-C6H4- C17H11ClN2O3S 326.73 228 0.497 S1 63 8.57 8.52
1l 3-C6H5-O-C6H4- C23H15ClN2O3 402.83 181 0.488 S1 60 6.95 6.94
1m 4-N(CH3)2-C6H4- C19H16ClN3O2 353.80 194 0.528 S1 50 11.88 11.84
TABLE-1:  PHYSICAL CONSTANTS OF 6-CHLORO3-[(2E)-3-ARYLPROP-2-ENOYL]CINNOLIN-4(3H)-
                   ONE
S1 = Ethyl acetate :  Hexane (3 : 7) S2 = Ethyl acetate : Hexane(2.5 : 7.5)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
2a C6H5- C17H10ClN3O2 323.73 166 0.462 S1 54 12.98 12.94
2b 3-Br-C6H4- C17H9BrClN3O2 402.63 210 0.483 S1 56 10.44 1042
2c 2-Cl-C6H4- C17H9Cl2N3O2 358.18 190 0.405 S2 51 11.73 11.72
2d 3-Cl-C6H4- C17H9Cl2N3O2 358.18 182 0.467 S1 62 11.73 11.63
2e 4-Cl-C6H4- C17H9Cl2N3O2 358.18 214 0.453 S1 63 11.73 11.70
2f 3,4-(OCH3)2-C6H4- C19H14ClN3O4 383.79 176 0.437 S1 59 10.95 10.92
2g 4-OCH3-C6H4- C18H12ClN3O3 353.76 200 0.478 S3 51 11.88 11.84
2h 4-SCH3-C6H4- C18H12ClN3O2S 369.83 210 0.405 S3 54 8.67 8.62
2i 3-C6H5-O-C6H4- C23H14ClN3O3 415.83 160 0.413 S1 50 10.11 10.10
2j 4-N(CH3)2-C6H4- C19H15ClN4O2 366.80 218 0.368 S1 62 15.27 15.24
TABLE-2:  PHYSICAL CONSTANTS OF 6-CHLORO-3-(5-ARYLISOXAZOLE-3-YL)-CINNOLIN-4(3H)-
                 ONE
S1 = Ethyl acetate : Hexane (1.4:8.6)
S2 = Ethyl acetate : Hexane (3:7)
S3 =  Ethyla acetate : Hexane (2.5:7.5)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
3a C6H5- C19H15ClN4O2 366.80 164 0.587 S1 55 15.27 15.25
3b 3-Br-C6H4- C19H14BrClN4O2 445.70 158 0.529 S1 58 12.57 12.54
3c 2-Cl-C6H4- C19H14Cl2N4O2 401.25 170 0.619 S1 59 13.96 13.95
3d 3-Cl-C6H4- C19H14Cl2N4O2 401.25 184 0.492 S1 54 13.96 13.94
3e 4-Cl-C6H4- C19H14Cl2N4O2 401.25 164 0.604 S1 61 13.96 13.96
3f 3,4-(OCH3)2-C6H4- C21H19ClN4O4 426.85 202 0.514 S1 64 13.13 13.12
3g 4-OCH3-C6H4- C20H17ClN4O3 396.83 186 0.565 S1 53 14.12 14.11
3h 4-SCH3-C6H4- C20H17ClN4O2S 412.89 188 0.551 S1 57 13.57 13.55
3i 3-NO2-C6H4- C19H14ClN5O4 411.80 168 0.456 S1 62 17.01 17.00
3j 2-OH-C6H4- C19H15ClN4O3 382.78 244 0.412 S1 50 14.64 14.63
3k 4-OH-C6H4- C19H15ClN4O3 382.78 258 0.467 S1 54 14.64 14.62
3l 3-C6H5-O-C6H4- C25H19ClN4O3 458.90 229 0.421 S1 51 12.21 12.20
3m 4-N(CH3)2-C6H4- C21H20ClN5O2 409.87 226 0.442 S1 50 17.09 17.05
TABLE-3:  PHYSICAL CONSTANTS OF 6-CHLORO-3-(1-ACETYL-5-ARYL-4,5-DIHYDRO-1H-
               PYRAZOL-3-YL)-CINNOLIN-4(3H)-ONE
S1 = Ethyl acetate : Hexane (3 : 7)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
4a C6H5- C23H17ClN4O 400.86 158 0.701 S1 65 13.98 13.94
4b 3-Br-C6H4- C23H16BrClN4O 479.76 150 0.524 S1 62 11.68 11.64
4c 2-Cl-C6H4- C23H16Cl2N4O 435.31 144 0.574 S2 54 12.87 12.85
4d 3-Cl-C6H4- C23H16Cl2N4O 435.31 122 0.594 S1 53 12.87 12.86
4e 4-Cl-C6H4- C23H16Cl2N4O 435.31 124 0.452 S3 48 12.87 12.85
4f 3,4-(OCH3)2-C6H4- C25H21ClN4O3 460.91 124 0.486 S3 45 12.16 12.15
4g 4-OCH3-C6H4- C24H19ClN4O2 430.89 140 0.553 S2 60 13.00 12.98
4h 4-SCH3-C6H4- C24H19ClN4OS 446.96 110 0.508 S1 55 12.54 12.52
4i 3-C6H5-O-C6H4- C29H21ClN4O2 49296 118 0.534 S1 51 11.37 11.34
4j 4-N(CH3)2-C6H4- C25H22ClN5O 443.93 164 0.614 S3 50 15.78 15.74
TABLE-4:  PHYSICAL CONSTANTS OF 6-CHLORO-3-(1-PHENYL-5-ARYL-4,5-DIHYDRO-1H-
               PYRAZOL-3-YL)-CINNOLIN-4(3H)-ONE
S1 = Benzene : Acetone (9 : 1)
S2 = Benzene : Acetone (8 : 2)
S3 =  Ethyla acetate : Hexane (2.5:7.5)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of Nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
5a C6H5- C20H12ClN5O 373.79 118 0.57 S1 55 18.74 18.72
5b 3-Br-C6H4- C20H11BrClN5O 452.69 196 0.51 S2 56 15.47 15.45
5c 2-Cl-C6H4- C20H11Cl2N5O 408.24 164 0.38 S2 42 17.16 17.15
5d 3-Cl-C6H4- C20H11Cl2N5O 408.24 210 0.69 S1 46 17.16 17.13
5e 4-Cl-C6H4- C20H11Cl2N5O 408.24 220 0.69 S3 49 17.16 17.15
5f 3,4-(OCH3)2-C6H4- C22H16ClN5O3 433.85 230D 0.65 S3 54 16.14 16.13
5g 4-OCH3-C6H4- C21H14ClN5O2 403.82 206 0.50 S2 53 17.34 17.33
5h 4-SCH3-C6H4- C21H14ClN5OS 419.88 198 0.39 S2 61 16.68 16.64
5i 3-C6H5-O-C6H4- C26H17ClN5O2 465.89 118 0.67 S3 48 15.03 15.02
5j 4-N(CH3)2-C6H4- C22H17ClN6O 416.86 238 0.58 S1 45 20.16 20.15
S1 = Benzene : Acetone (5 :5)
S2 = Benzene : Mrthanol (7 : 3)
S3 = Benzene : Acetone (3 : 7)
TABLE-5:  PHYSICAL CONSTANTS OF 2-AMINO-4-ARYL-6-(6-CHLORO-4-OXO-3,4-DIHYDRO
                   CINNOLIN-3-YL)NICOTINONITRILE
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
6a C6H5- C20H11ClN4O2 374.78 176 0.35 S1 51 14.95 14.62
6b 3-Br-C6H4- C20H10BrClN4O2 453.68 162 0.46 S2 53 12.35 12.34
6c 2-Cl-C6H4- C20H10Cl2N4O2 409.23 154 0.54 S3 58 13.69 13.65
6d 3-Cl-C6H4- C20H10Cl2N4O2 409.23 180 0.48 S1 46 13.69 13.66
6e 4-Cl-C6H4- C20H10Cl2N4O2 409.23 186 0.38 S2 59 13.69 13.65
6f 3,4-(OCH3)2-C6H4- C22H15ClN4O4 434.83 172 0.48 S2 51 12.88 12.84
6g 4-OCH3-C6H4- C21H13ClN4O3 404.81 180 0.49 S3 55 13.84 13.81
6h 4-SCH3-C6H4- C21H13ClN4O2S 420.87 198 0.55 S1 48 13.31 13.25
6i 3-C6H5-O-C6H4- C26H15ClN4O3 466.88 128 0.52 S3 49 12.00 11.97
6j 4-N(CH3)2-C6H4- C22H16ClN5O2 417.85 158 0.31 S3 52 16.76 16.74
TABLE-6:  PHYSICAL CONSTANTS OF 4-ARYL-6-(6-CHLORO-4-OXO-3,4-DIHYDROCINNOLIN-3-YL)-
                2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
S1 = Ethyl acetate : Hexane (1 : 9)
S2 = Ethyl acetate : Hexane (2 : 8)
S3 = Acetone : Benzene (1.5 : 8.5)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
7a C6H5- C20H13ClN4O2 376.79 186 0.35 S1 54 14.87 14.85
7b 3-Br-C6H4- C20H12BrClN4O2 455.69 198 0.45 S2 54 12.29 12.27
7c 2-Cl-C6H4- C20H12Cl2N4O2 411.24 265 0.42 S1 52 13.62 13.61
7d 3-Cl-C6H4- C20H12Cl2N4O2 411.24 226 0.52 S1 55 13.62 13.60
7e 4-Cl-C6H4- C20H12Cl2N4O2 411.24 270 0.57 S2 54 13.62 13.62
7f 3,4-(OCH3)2-C6H4- C22H17ClN4O4 436.85 >300 0.38 S3 52 12.83 12.81
7g 4-OCH3-C6H4- C21H15ClN4O3 406.82 220 0.55 S2 53 13.77 13.75
7h 4-SCH3-C6H4- C21H15ClN4O2S 422.89 285D 0.49 S2 51 13.25 13.24
7i 3-C6H5-O-C6H4- C26H17ClN4O3 468.89 189 0.51 S2 54 11.95 11.94
7k 4-N(CH3)2-C6H4- C22H18ClN5O2 419.86 >300 0.63 S1 56 16.68 16.64
TABLE-7:  PHYSICAL CONSTANTS OF 2-AMINO-4-ARYL-6-(6-CHLORO-4-OXO-3,4-DIHYDRO
                   CINNOLIN-3-YL)-4H-PYRAN-3-CARBONITRILE
S1 = Ethyl acetate : Hexane (1:9), S2 = Ethyl acetate : Hexane (2.5 : 7:5), S3 = Acetone : Benzene (2 : 8)
Sr. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
No. Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
8a C6H5- C23H19ClN2O4 422.86 212 0.46 S1 57 6.62 6.61
8b 3-Br-C6H4- C23H18BrClN2O4 501.76 224 0.41 S1 58 5.58 5.54
8c 2-Cl-C6H4- C23H18Cl2N2O4 457.31 118 0.52 S1 60 6.13 6.11
8d 3-Cl-C6H4- C23H18Cl2N2O4 457.31 186 0.37 S1 54 6.13 6.12
8e 4-Cl-C6H4- C23H18Cl2N2O4 457.31 132 0.44 S2 55 6.13 6.10
8f 3,4-(OCH3)2-C6H4- C25H23ClN2O6 482.91 238 0.56 S2 54 5.80 5.79
8g 4-OCH3-C6H4- C24H21ClN2O5 452.89 146 0.34 S2 58 6.19 6.17
8h 4-SCH3-C6H4- C24H21ClN2O4S 468.95 156 0.38 S3 54 5.97 5.99
8i 3-C6H5-O-C6H4- C29H23ClN2O5 514.96 164 0.42 S3 55 5.44 5.43
8J 4-N(CH3)2-C6H4- C25H24ClN3O4 465.93 142 0.49 S1 54 9.02 9.01
8K C9H6ClN C26H19Cl2N3O4 508.27 159 0.47 S3 53 8.27 8.24
TABLE-8:  PHYSICAL CONSTANTS OF ETHYL-6-ARYL-4-(6-CHLORO-4-OXO-3,4-DIHYDRO
              CINNOLIN-3-YL)-2-OXO-CYCLOHEX-3-ENE-1-CARBOXYLATE
S1 = Ethyl acetate : Hexane (2 : 8)
S2= Ethyl acetate : Hexane (3 : 7)
S3= Acetone : Benzene (1 :9)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
9a C6H5- C21H15ClN4O2 390.82 210 0.48 S1 45 14.34 14.33
9b 3-Br-C6H4- C21H14BrClN4O2 469.72 198 0.54 S1 43 11.93 11.90
9c 2-Cl-C6H4- C21H14Cl2N4O2 425.27 220 0.38 S1 48 13.17 13.15
9d 3-Cl-C6H4- C21H14Cl2N4O2 425.27 174 0.36 S2 46 13.17 13.14
9e 4-Cl-C6H4- C21H14Cl2N4O2 425.27 170 0.49 S3 45 13.17 13.15
9f 3,4-(OCH3)2-C6H4- C23H19ClN4O4 450.87 178 0.55 S2 42 12.43 12.44
9g 4-OCH3-C6H4- C22H17ClN4O3 420.85 159 0.54 S1 43 13.31 13.30
9h 4-SCH3-C6H4- C22H17ClN4O2S 436.92 204 0.41 S1 45 12.82 12.81
9i 3-C6H5-O-C6H4- C27H19ClN4O3 482.92 181 0.59 S3 42 11.60 11.59
9j 4-N(CH3)2-C6H4- C23H20ClN5O2 433.89 194 0.51 S3 49 16.14 16.13
9k C9H6ClN C24H15Cl2N5O2 476.31 226 0.61 S2 53 14.22 14.20
TABLE-9:  PHYSICAL CONSTANTS OF 6-CHLORO-3-(4-ARYL-3-OXO-3,3a,4,5-TETRAHYDRO-2H-
                  INDAZOL-6-YL)-CINNOLIN-4(3H)-ONE
S1 = Ethyl acetate : Hexane (1.4:8.6)
S2 = Ethyl acetate : Hexane (3:7)
S3 =  Ethyla acetate : Hexane (2.5:7.5)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
10a C6H5- C23H16ClN3OS 417.91 109 0.590 S1 65 10.05 10.04
10b 3-Br-C6H4- C23H15BrClN3OS 496.81 140 0.546 S2 66 8.46 8.44
10c 2-Cl-C6H4- C23H15Cl2N3OS 452.36 130 0.482 S1 59 9.29 9.25
10d 3-Cl-C6H4- C23H15Cl2N3OS 452.36 125 0.637 S1 52 9.29 9.24
10e 4-Cl-C6H4- C23H15Cl2N3OS 452.36 125 0.593 S1 54 9.29 9.26
10f 3,4-(OCH3)2-C6H4- C25H20ClN3O3S 477.96 115 0.545 S2 57 8.79 8.75
10g 4-OCH3-C6H4- C24H18ClN3O2S 447.94 117 0.470 S2 55 9.38 9.36
10h 4-SCH3-C6H4- C24H18ClN3OS2 464.00 110 0.567 S1 53 9.06 9.04
10i 3-C6H5-O-C6H4- C29H20ClN3O2S 510.01 100 0.518 S1 64 8.24 8.21
10j 4-N(CH3)2-C6H4- C25H21ClN4OS 460.98 95 0.488 S2 65 12.15 12.13
TABLE-10:  PHYSICAL CONSTANTS OF 6-CHLORO-3-(2-ARYL-2,3-DIHYDRO-1,5-BENZOTHIAZEPIN-
                  4-YL)-CINNOLIN-4(3H)-ONE
S1 = Ethyl acetate : Hexane (1.5 : 8.5)
S2 = Ethyl acetate : Hexane (2.4 : 7.6)
Sr. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
 No. Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
11a C6H5- C18H12ClN5OS 381.84 168 0.373 S2 64 18.34 18.33
11b 3-Br-C6H4- C18H11BrClN5OS 460.74 125 0.394 S1 65 15.20 15.18
11c 2-Cl-C6H4- C18H11Cl2N5OS 416.28 178 0.291 S1 66 16.82 16.80
11d 3-Cl-C6H4- C18H11Cl2N5OS 416.28 120 0.437 S1 65 16.82 16.82
11e 4-Cl-C6H4- C18H11Cl2N5OS 416.28 150 0.494 S2 64 16.82 16.81
11f 3,4-(OCH3)2-C6H3- C20H16ClN5O3S 441.89 130 0.444 S3 59 15.85 15.846
11g 3,4,5-(OCH3)3-C6H2- C21H18ClN5O4S 471.92 140 0.541 S3 58 14.84 14.81
11h 4-OCH3-C6H4- C19H14ClN5O2S 411.87 140 0.423 S1 55 16.37 16.35
11i 2-OH-C6H4- C18H12ClN5O2S 397.84 190 0.535 S1 57 17.60 17.58
11j 3-C6H5-O-C6H4- C24H16ClN5O2S 473.94 118 0.425 S2 59 14.78 14.77
11k 4-N(CH3)2-C6H4- C20H17ClN6OS 424.91 145 0.295 S1 62 19.78 19.74
TABLE-11:  PHYSICAL CONSTANTS OF (1E)-ARYL-[4-(6-CHLORO-4-OXO-3,4-DIHYDROCINNOLIN-3-
                 YL)-1,3-THIAZOL-2-YL]HYDRAZONE
S1 = Ethyl acetate : Hexane (2:8)
S2 = Ethyl acetate : Hexane (0.5:9.5)
S3 = Ethyl acetate : Hexane (1:9)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
12a C6H5- C18H12ClN5O 349.77 245 0.69 S1 56 20.02 20.01
12b 3-Br-C6H4- C18H11BrClN5O 428.67 230 0.54 S2 54 16.34 16.32
12c 2-Cl-C6H4- C18H11Cl2N5O 384.22 282 0.68 S2 49 18.23 18.22
12d 3-Cl-C6H4- C18H11Cl2N5O 384.22 180 0.56 S1 48 18.23 18.21
12e 4-Cl-C6H4- C18H11Cl2N5O 384.22 134 0.71 S3 47 18.23 18.23
12f C4H3-O- C16H10ClN5O2 339.74 308 0.54 S1 45 20.61 20.58
12g 4-OCH3-C6H4- C19H14ClN5O2 379.80 304 0.48 S3 46 18.44 18.42
12h 4-SCH3-C6H4- C19H14ClN5OS 395.80 260 0.62 S2 48 17.69 17.66
12i 3-C6H5-O-C6H4- C24H16ClN5O2 441.87 175 0.39 S1 52 15.85 15.81
12j 4-N(CH3)2-C6H4- C20H17ClN6O 392.84 160 0.48 S2 53 21.39 21.38
TABLE-12:  PHYSICAL CONSTANTS OF 3-(2-AMINO-6-ARYLPYRIMIDIN-4-YL)-6-CHLOROCINNOLIN-
                  4(3H)-ONE
S1 = Ethyl acetate : Hexane (1.5 : 8.5)
S2 = Ethyl acetate : Hexane (2 : 8)
S3 = Ethyl acetate : Hexane (3: 7)
Sr. No. R- Molecular Molecular M. P. Rf Solvent Yield % of nitrogen
Formula Weight 0C Value System % Calcd Found
1 2 3 4 5 6 7 8 9 10
13a C6H5- C18H13ClN4OS 368.84 149 0.48 S1 54 15.19 15.17
13b 3-Br-C6H4- C18H12BrClN4OS 447.74 108 0.69 S1 54 12.51 12.50
13c 2-Cl-C6H4- C18H12Cl2N4OS 403.89 156 0.52 S2 56 13.89 13.88
13d 3-Cl-C6H4- C18H12Cl2N4OS 403.89 182 0.50 S1 55 13.89 13.87
13e 4-Cl-C6H4- C18H12Cl2N4OS 403.89 188 0.54 S3 53 13.89 13.88
13f 3,4-(OCH3)2-C6H4- C20H17ClN4O3S 428.89 290 0.68 S3 58 13.06 13.04
13g 4-OCH3-C6H4- C19H15ClN4O2S 398.87 178 0.63 S1 49 14.05 14.03
13h 4-SCH3-C6H4- C19H15ClN4OS2 414.93 145 0.65 S3 47 13.50 13.47
13i 4-OH-C6H4- C18H13ClN4O2S 384.84 140 0.67 S3 51 14.56 14.55
13j 3-C6H5-O-C6H4- C24H17ClN4O2S 460.94 188 0.61 S2 50 12.16 12.15
13k 4-N(CH3)2-C6H4- C20H18ClN5OS 411.91 164 0.57 S2 54 17.00 12.98
TABLE-13:  PHYSICAL CONSTANTS OF 6-CHLORO-3-(6-ARYL-2-MERCAPTO-3,4-DIHYDRO
                 PYRINIDIN-4-YL)-4(3H)-ONE
S1 = Ethyl acetate : Hexane (1.5 : 8.5)
S2 = Ethyl acetate : Hexane (2 : 8)
S3 = Ethyl acetate : Hexane (3: 7)
